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LRRK2 Biology from structure to
dysfunction: research progresses, but the
themes remain the same
Daniel C. Berwick1*†, George R. Heaton2†, Sonia Azeggagh1 and Kirsten Harvey2*
Abstract
Since the discovery of leucine-rich repeat kinase 2 (LRRK2) as a protein that is likely central to the aetiology of
Parkinson’s disease, a considerable amount of work has gone into uncovering its basic cellular function. This effort
has led to the implication of LRRK2 in a bewildering range of cell biological processes and pathways, and probable
roles in a number of seemingly unrelated medical conditions. In this review we summarise current knowledge of
the basic biochemistry and cellular function of LRRK2. Topics covered include the identification of phosphorylation
substrates of LRRK2 kinase activity, in particular Rab proteins, and advances in understanding the activation of
LRRK2 kinase activity via dimerisation and association with membranes, especially via interaction with Rab29. We
also discuss biochemical studies that shed light on the complex LRRK2 GTPase activity, evidence of roles for LRRK2
in a range of cell signalling pathways that are likely cell type specific, and studies linking LRRK2 to the cell biology
of organelles. The latter includes the involvement of LRRK2 in autophagy, endocytosis, and processes at the trans-
Golgi network, the endoplasmic reticulum and also key microtubule-based cellular structures. We further propose a
mechanism linking LRRK2 dimerisation, GTPase function and membrane recruitment with LRRK2 kinase activation
by Rab29. Together these data paint a picture of a research field that in many ways is moving forward with great
momentum, but in other ways has not changed fundamentally. Many key advances have been made, but very
often they seem to lead back to the same places.
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Background
Leucine-rich repeat kinase 2 (LRRK2) is an enigmatic
protein that has been at the centre of an increasing
amount of research since its discovery in 2004. Al-
though LRRK2 has been implicated in a number of hu-
man diseases, the basic function of this protein remains
poorly understood. Debates span all levels of research;
from biochemistry – how do the two enzymatic activ-
ities of LRRK2 relate to each other, and what effects do
disease-causing mutation have? – to cell biology –
what processes does LRRK2 mediate, and what are its
phosphorylation substrates? Even the cell types this
protein is most relevant to are under discussion. The
study of LRRK2 continues to produce more questions
than answers.
In this review we summarise the current state of the
LRRK2 field, covering first the connections between
LRRK2 and a surprising number of clinical conditions,
before progressing to its mode of action and the cell bio-
logical processes it mediates. Although many details are
missing and the field remains a long way from agree-
ment, this is an exciting time for LRRK2 biology. Im-
portant advances have been made in distinct areas
providing some consensus and a feeling that the field
has momentum. In particular, breakthroughs relevant to
disease treatment may be close.
LRRK2 in disease
In this section we summarise the genetic connections
between the LRRK2 gene and human disease, starting
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first with the condition that LRRK2 is most strongly
linked to: Parkinson’s disease (PD).
PD is the second most common neurodegenerative dis-
ease worldwide, with a lifetime risk estimated to be
around 2% [1, 2]. Initially described by James Parkinson in
1817 as a “shaking palsy” [3], PD remains incurable 200
years later. The major risk factor is age, and since the
world’s population is ageing, understanding the underlying
PD pathomechanism is increasingly important.
Over the last 15-20 years a considerable amount of
work has gone into determining the genetic causes of
PD. Although PD is usually sporadic or idiopathic, it has
long been known that around 1 in 10 PD patients have a
family history of PD, so research initially focused on
families who carry gene mutations that are sufficient to
cause PD (i.e. monogenic forms of PD). More recently,
PD genetics has expanded to more powerful genome-
wide association studies (GWAS) that compare genetic
markers from thousands of individuals with sporadic PD
with genetic markers from similarly large numbers of
healthy controls. GWAS are able to identify significant
differences in frequency of particular SNPs that nomin-
ate loci containing gene variants associated with PD inci-
dence. Some identified risk variants may be insufficient
to cause disease by themselves, but can still have a sig-
nificant impact on an individual’s lifetime risk of devel-
oping the condition.
In 2004 research into familial PD led two groups
working independently to clone the gene that became
known as LRRK2 [4, 5]. Subsequent work has identified
at least 9 missense mutations in LRRK2 that appear suf-
ficient to cause PD (i.e. pathogenic mutations), as well as
other missense changes that affect PD risk, including
both pathogenic and protective risk variants. We expand
upon these below. Pathogenic LRRK2 variants have been
suggested to represent the largest known cause of PD
worldwide, although this is hard to know for sure given
that incidence varies between populations and not all
populations have been thoroughly surveyed. The highest
incidence is in parts of North Africa, where LRRK2 mu-
tations cause as much as 40% of all PD cases [6].
More recently LRRK2 has been linked to PD a second
time through GWAS [6]. These studies have repeatedly
shown linkage of PD risk to LRRK2, and meta-analysis
indicates LRRK2 is one of the more important genomic
loci influencing the condition [7]. Thus, LRRK2 muta-
tions make a large contribution towards both sporadic
and familial forms of PD.
Remarkably, LRRK2 has also been connected genetic-
ally to a number of chronic inflammatory conditions, be-
ginning in 2008 with linkage to Crohn’s disease (CD), an
inflammation of the terminal ileum, which was found via
meta-analysis with subsequent replication of three separ-
ate GWAS investigations [8]. Initial studies were unable
to distinguish between LRRK2 and the neighbouring
MUC19 gene, which arguably delayed interest in LRRK2
in this context. Although the linkage is relatively weak
compared to other CD genes, the observation has been
reproduced in a number of studies, e.g. [9–11], and very
persuasively, both pathogenic and protective LRRK2 var-
iants have been reported [9]. It is worth noting that CD
is one of two distinct chronic inflammatory intestinal
disorders that are grouped together as inflammatory
bowel disease, the other being ulcerative colitis, an in-
flammation of the colon [12]. This has led to LRRK2
sometimes being reported as a risk factor for inflamma-
tory bowel disease, even though linkage is stronger (and
may be specific) to CD.
Just a year later, linkage to LRRK2 was reported in
GWAS of Chinese leprosy patients [13], a result that has
been replicated in some [14, 15] but not all subsequent
studies [16]. Leprosy (also known as Hansen’s disease) is
a chronic inflammatory condition caused by Mycobacter-
ium leprae infection of the skin and peripheral nerves.
Fascinatingly, this work also implicated a number of
genes in leprosy risk that had previously been linked to
CD, including NOD2 and RIPK2 [13, 17], suggesting that
these seemingly unrelated conditions may have similar
pathomechanisms [17]. By contrast, similarities between
leprosy and tuberculosis (TB), the third inflammatory
disease linked to LRRK2, were already well established
when this connection was reported via a meta-analysis
of nine separate GWAS investigations of TB patients
[18]. Unlike leprosy, TB affects the lungs, but both con-
ditions are caused by mycobacterial infection and simi-
larities between their genetic risks have been known
since the late 1990’s [19, 20]. The lack of any replication
studies and the relatively weak linkage that is implied by
meta-analysis of nine studies means the role of LRRK2
in TB should be treated with caution. Nonetheless, the
similarities of TB to leprosy, and a recent publication
demonstrating elegantly that LRRK2 kinase activity af-
fects Mycobacterium tuberculosis infection in vitro and
in mouse models make this a very interesting story to
follow [21].
Taken together with the involvement of LRRK2 in a
number of immune cell-relevant signalling pathways,
which we expand upon below, the GWAS implication
of LRRK2 in the pathogenesis of three separate
chronic inflammatory conditions creates a powerful
body of work arguing for an essential function of
LRRK2 in inflammatory responses that have potential
implications for PD. Indeed, the connection between
LRRK2 and CD forms part of a body of evidence that
has been used to create a theory that PD may be a
low-grade inflammatory bowel disease [22]. We would
not dispute the strength of this argument, but it does
not reconcile the linkage of LRRK2 to leprosy and TB,
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which are in general not primarily gut disorders. We
also note a report of elevated LRRK2 expression in the
nasal linings of individuals with chronic rhinosinusitis
[23]. It may thus be the case that it is chronic inflam-
mation more generally and not specifically in the gut
that increases the risk of PD. Alternatively, the roles of
LRRK2 in these inflammatory conditions and in PD
may yet be unrelated.
A final category of disease linked to LRRK2 is cancer.
Individuals with the most common pathogenic LRRK2
mutation, G2019S, have been reported to have an in-
creased risk of developing cancers [24–26] although
this is disputed [27, 28]. This link to cancer is slightly
surprising, as it is fairly well established that individuals
with PD have a reduced incidence of almost all cancers
apart from melanoma and other skin cancers [29]. As
such the role of LRRK2 in cancer remains controver-
sial, but serves to further the idea that LRRK2 is in-
volved in more processes than are suggested by its
links to PD alone.
LRRK2 protein structure and function
LRRK2 is a highly unusual protein, containing four protein-
protein interaction domains, as well as domains conferring
two distinct enzymatic activities [6]. As defined by its kinase
domain, LRRK2 is a serine-threonine kinase capable of
autophosphorylating residues elsewhere in LRRK2, as well
as phosphorylating a select group of heterologous sub-
strates (see next section). The second enzymatic activity is
GTPase activity, which is mediated by the Roc (Ras of com-
plex proteins) domain. Throughout evolution Roc domains
are always accompanied by a COR (C-terminal of Roc) do-
main [30] and thus, even though both Roc and COR form
distinct globular structures and are individual domains in
the conventional sense, they are functionally inseparable
and considered by many a RocCOR tandem domain. The
mode of action of the LRRK2 GTPase is discussed in the
next section.
The structure of LRRK2 is depicted in Fig. 1. The key
points, which we expand upon in the next two sections,
are the two enzymatic activities and how they relate to
each other, the capacity of LRRK2 to switch between di-
meric and monomeric forms and how this may affect its
function, as well as the remarkable number of reported
interacting proteins that suggest LRRK2 likely acts in
larger multiprotein complexes.
LRRK2 kinase activity
Of the two LRRK2 enzymatic activities, the majority of
work has focussed on its kinase activity. There are a num-
ber of reasons for this, the most important being the early
observation that the most common pathogenic variant,
G2019S, displays a modest but reproducible elevation of
kinase activity, when assayed by measuring the phosphor-
ylation of a substrate peptide in vitro [32]. This led to the
hypothesis that all pathogenic mutations would be gain-
of-function that cause PD via hyperphosphorylation of
substrate proteins, which in turn triggered considerable ef-
forts to develop pharmacological inhibitors of LRRK2 kin-
ase activity.
The path from these initial kinase assays to the pos-
ition we are in today has been far from plain sailing.
Major problems included the failure of other patho-
genic mutations to display convincingly increased kin-
ase activity in vitro, and the remarkable difficulties in
identifying agreed physiological substrates. For a long
Fig. 1 LRRK2 domain structure and function. LRRK2 contains a catalytic core, conferring GTPase activity via the RocCOR domain and kinase
activity, embedded in ARM, ANK, LRR and WD40 protein-protein interaction domains. LRRK2 mutations are indicated with a star above the
domain structure. LRRK2 is regulated by autophosphorylation of the kinase and Roc domain. Heterophosphorylation by CK1α, IKK and PKA, and
dephosphorylation by PP1 regulates interaction with 14-3-3 proteins affecting LRRK2 localisation. Rab29 recruits LRRK2 to the TGN further
depicted in detail in Fig. 2.
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time, increased kinase activity was the dominant idea
in the LRRK2 field, but with a growing dose of scep-
ticism: perhaps the elevated kinase activity of G2019S
in vitro was a red herring?
However the eventual identification of physiological
substrates, first with the description of a robust LRRK2
autophosphorylation site, serine-1292 [33], and then,
more significantly, with the description of a group of
Rab small GTPases (Rab3A/B/C/D, Rab8A/B, Rab10,
Rab12, Rab29, Rab35, Rab43) as heterologous substrates
[34], has cleared up most of the doubt. Most notably, au-
tophosphorylation of serine-1292 and Rab protein phos-
phorylation are both robustly and reproducibly increased
by pathogenic LRRK2 variants, both in vitro and in
cultured cells. Presumably, G2019S elevates LRRK2 kin-
ase activity and thus increases the phosphorylation of
physiological targets and small peptides alike, whereas
the other pathogenic variants act independently of kin-
ase activity, perhaps by facilitating interactions with sub-
strate proteins. Phosphorylation of these Rab proteins by
LRRK2 perturbs their ability to bind both upstream
regulatory proteins and downstream effector proteins
[34, 35], and convincing effects of Rab phosphorylation
on cell biological processes, including ciliogenesis and
rates of endocytosis, have been described [35, 36]. Full
mechanistic details remain to be established, but it has
been postulated that phosphorylated Rab proteins be-
come trapped on intracellular membranes, unable to re-
locate to the compartments in which they are needed
]37]. We expand upon the consequences of Rab phos-
phorylation later in this review. In any case, after a fairly
bumpy road, the increased kinase activity hypothesis
looks to be correct, and a large amount of work is now
focussed on LRRK2 and Rab protein phosphorylation,
and enthusiasm for identifying new substrate proteins is
renewed. It must also be said that the success of the Rab
phosphorylation story appears to be justifying the con-
siderable investment into developing LRRK2 kinase in-
hibitors as potential treatments for PD. LRRK2 kinase
inhibitors have been reviewed by others (e.g. [38]) and
are in early phase clinical trials; results are awaited with
cautious optimism.
So, if Rabs are downstream of LRRK2 kinase activity, what
is upstream? As we and others have argued, a major theme
for LRRK2 appears to be as signalling scaffold [39, 40], and
a number of signalling mechanisms have been reported to
function up and downstream of LRRK2. But if we limit our-
selves to pathways that specifically act on LRRK2 kinase ac-
tivity we find ourselves returning to Rab GTPases and
specifically Rab29. Rab29 (then known as Rab7L1) first en-
tered the radar of LRRK2 researchers as a modifier of
LRRK2 PD risk, and a PD risk gene in its own right, that
physically associates with LRRK2 in cells and rescues certain
cellular phenotypes associated with the LRRK2 G2019S
variant, which we expand upon below [41]. This interaction
was confirmed shortly afterwards in an unbiased screen for
novel LRRK2 binding proteins [42]. These and subsequent
studies have shown that Rab29 recruits LRRK2 to the Golgi
complex and this interaction appears to increase the kinase
activity of LRRK2, as determined by both LRRK2 serine-
1292 phosphorylation [33], and the phosphorylation of Rab
substrate proteins [43, 44]. Interestingly, the phosphorylation
of Rab29 by LRRK2 appears to weaken its ability to enhance
LRRK2 kinase activity, suggesting that in addition to a
Rab29-LRRK2-Rab signalling axis, there may also be a
Rab29-LRRK2-Rab29 negative feedback mechanism [43].
Since these are recent developments, the consequences
of LRRK2 activation by Rab29 are not yet fully under-
stood, although we discuss its potential role in cell bio-
logical processes later in this article. Despite this, the
potential impact on the study of LRRK2 of having Rab29
as a LRRK2 kinase activator makes this a very useful
breakthrough indeed.
LRRK2 GTPase activity
LRRK2 GTPase activity has received less attention
than that of the kinase domain, yet the number of
pathogenic mutations located in the Roc and COR
domains indicate LRRK2 GTPase activity is no less
important. As we have reviewed elsewhere [45], all
pathogenic RocCOR mutations tested either increase
affinity for GTP or decrease rates of GTP hydrolysis
(or do both), all of which can be expected to lead to
more LRRK2 in the GTP-bound state (as opposed to
GDP-bound or not bound to guanine nucleotides).
Corroborating this further, the R1398H Roc domain
variant, which is protective against PD and CD [9],
displays weakened GTP binding and an increased rate
of GTP hydrolysis [9, 46].
However, the mechanism by which LRRK2 hydrolyses
GTP to GDP and then recycles back to GTP-bound is still
unclear, with many studies limited by just using the isolated
Roc or RocCOR domains. Nonetheless, since there is a
growing agreement that the COR domain is required for
normal LRRK2 GTPase function, the consensus is that the
Roc domain does not act in a manner analogous to small
GTPases. This view is supported further by the lack of clas-
sical GAPs and GEFs for LRRK2. Although some enzyme
kinetics studies suggest a requirement for additional pro-
teins to facilitate GTP hydrolysis or guanine nucleotide ex-
change [47, 48], none of the GAPs and GEFs that have
been proposed (ARHGEF7, ArfGAP1, and RGS2 [49–51]),
are reported to bind directly to the Roc domain as would
be expected for the GAPs and GEFs of a small GTPase.
Instead, most theories for LRRK2 GTPase function are
based around a so-called GTPase Activated by Dimerisa-
tion (GAD) model, which is drawn largely from studies
using homologous RocCOR domain containing proteins.
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Inferences from experiments that use proteins from
distantly related species must clearly be made with cau-
tion, and it is worth noting that the C.tepidum RocCOR
protein in which most work has been done requires the
intermolecular exchange of Roc domain lysine residues
that are not present in human LRRK2 to form an active
site [52]. Nonetheless the structure of the C.tepidum
RocCOR fits very well to the structure of full-length
human LRRK2 dimers as revealed by negative-stain
electron microscopy [53], suggesting that at the very
least, LRRK2 is a “GAD-like” GTPase.
In the GAD model, LRRK2 functions as a homodimer,
with dimerisation mediated by the COR domain, creat-
ing a structure where the Roc domains of each LRRK2
molecule face each other [54]. It was previously assumed
that GTP hydrolysis was achieved by the two Roc do-
mains coming together, but more recent evidence con-
tradicts this idea. Specifically, Deyaert and colleagues
have shown that the isolated RocCOR domain is primar-
ily dimeric when bound to GDP or when no nucleotides
are present, but monomeric when GTP bound [31].
Based on this, they propose a model where LRRK2 is re-
quired to be in the GDP-bound state to dimerise, and
the exchange of GDP for GTP triggers the dissociation
of the dimer, with GTP hydrolysis occurring subse-
quently when monomeric [31, 54]. These observations
must be treated with caution as they were not performed
using full-length LRRK2, which has additional domains
that may support dimerisation (in particular the C-
terminal WD40 domain [55]), but they are fascinating.
We discuss their implications for LRRK2 as a whole fur-
ther in the next section.
As a final point of comment on LRRK2 GTPase activity,
it is worth observing that although many proteins have
been reported to bind the Roc domain, no heterologous
interacting proteins that bind to the Roc domain when
only in GTP- or GDP-bound states have been reported.
This is perhaps slightly surprising. Guanine nucleotide-
specific interactions with effector molecules are how small
GTPases typically act, so it would not be unreasonable to
hypothesise that one or more proteins functioning down-
stream of LRRK2 might interact with the Roc or RocCOR
domains in a GTP- or GDP-dependent manner. Since it
took such a long time for the LRRK2 field to agree on any
widely accepted substrates of LRRK2 kinase activity, it
would be unwise to exclude the possibility that GTPase ef-
fector proteins exist, but at present the most likely pur-
pose of this enzymatic activity appears to be control of
LRRK2 itself.
Integrating LRRK2 kinase activity, GTPase activity and
dimerisation – a single mechanism?
The proposed GTP/GDP-dependent switch between
monomeric and dimeric forms of LRRK2 is intriguing.
LRRK2 has long been known to exist in cells as both
monomers and dimers, with evidence that the two
LRRK2 species have different properties and subcellu-
lar locations. Specifically, dimeric forms of LRRK2 are
enriched on intracellular membranes and possess en-
hanced kinase activity (as judged by in vitro assays of
autophosphorylation), whereas monomeric LRRK2 is
predominantly cytosolic with lower kinase activity
[56–59]. LRRK2 dimerisation is clearly an important
regulatory mechanism.
Nonetheless, these results also present a conflict. On
the one hand, all pathogenic LRRK2 mutants display in-
creased phosphorylation of Rab proteins, a phosphoryl-
ation event that takes place on intracellular membranes,
which suggests pathogenic mutants are more likely to be
dimeric. But on the other hand, pathogenic RocCOR
mutants shift LRRK2 into a GTP-bound state, which
based on Deyaert et al’s work predicts a preference for
the monomeric form. Indeed, pathogenic mutations have
been reported to weaken dimerisation of isolated Roc-
COR domain fragments [46, 60, 61], although not the
full-length protein [60].
So how might these observations be reconciled? The
caveat that the Deyaert study was not made on full
length LRRK2 should again be stressed here, but fascin-
atingly, their data do point to an explanation. Specific-
ally, their results suggest that pathogenic mutations may
not actually decrease GTPase activity per se, but instead
slow the monomerisation of GTP-bound RocCOR di-
mers, which their data indicate to be a prerequisite step
before GTP hydrolysis [31]. As such, these pathogenic
mutations can be expected to trap LRRK2 as GTP-
bound dimers, which would be entirely consistent with
elevated substrate phosphorylation.
Integrating this with LRRK2 kinase activation by mem-
brane recruitment by active GTP-bound Rab29 yields
the following theoretical model for LRRK2 activation,
which is outlined in Fig. 2. Interactions between the an-
kyrin domain of LRRK2 and GTP-Rab29 leads to mem-
brane recruitment of LRRK2 monomers, creating a
microdomain of high LRRK2 concentration, which helps
promote LRRK2 dimerisation. The combination of
membrane localisation and dimerisation leads to Rab
protein phosphorylation. GDP dissociates from LRRK2
to be replaced by GTP, favouring the dissociation of
LRRK2 dimers, and the return of monomeric LRRK2 to
the cytosol. However, binding to GTP-Rab29 might be
expected to stabilise LRRK2 dimers, such that the release
and monomerisation of LRRK2 could require Rab29 to
hydrolyse its own bound guanine nucleotide and enter
an inactive GDP-bound conformation. As such, Rab29
may enhance LRRK2 kinase activity in three ways: first,
by recruiting LRRK2 to the subcellular localisation
where its substrates are; second, by creating a LRRK2-
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rich microenvironment that favours dimerisation and in-
creased kinase activity; and third, by stabilising LRRK2
dimers and preventing their monomerisation when
GTP-bound. Pathogenic mutants synergise with Rab29
to further enhance substrate phosphorylation, by either
further stabilising LRRK2 dimers (RocCOR mutants), or
by elevating intrinsic LRRK2 kinase activity (G2019S).
These observations therefore point to a model where
LRRK2 dimerisation promotes kinase activity, and the
GTPase activity acts to determine the duration for which
dimers exist. However, it must be noted that the relation-
ship between LRRK2 GTPase and kinase activities and di-
merisation is more complicated yet, since a number of
autophosphorylation sites have been reported within the
LRRK2 Roc domain. The effect of this autophosphorylation
is poorly understood, but likely indicates a bi-directional re-
lationship between these two enzymatic activities. (Curi-
ously, the LRRK2 kinase domain is itself the site of a
number of autophosphorylation sites, suggesting yet an-
other layer of complexity.) In addition, how WD40 domain
dimerisation integrates into this is another source of confu-
sion. On the one hand loss of this domain prevents dimer
formation and reduces the neurotoxicity of LRRK2 [62],
but on the other hand, low resolution structural studies of
dimeric full-length LRRK2 do not position the two WD40
domains in sufficiently close proximity to interact [53],
while PD-associated WD40 domain variants that lie within
the dimerisation interface weaken interaction between
isolated WD40 domains [63]. Clearly, many key experi-
ments remain to be performed.
LRRK2 signalling
Beyond the signalling mechanisms involving LRRK2
mentioned above (phosphorylation of Rab proteins, ac-
tivation of LRRK2 kinase activity by Rab29, and modu-
lation of GTPase function by ARHGEF7, ArfGAP1, and
RGS2), LRRK2 has been linked to a variety of different
signal transduction pathways, which we summarise in
this section. These include pathways that are relevant
to all or most cell types, and others that are probably
most important in immune cells, which likely indicates
that LRRK2 has a number of signalling functions that
may be both cell and context specific. Most fascinat-
ingly, within these various roles there is little evidence
of LRRK2 acting as kinase, with most studies suggesting
a scaffolding function, likely exerting an indirect modu-
latory effect on signalling.
Signalling upstream of LRRK2
In addition to autophosphorylation by its own kinase do-
main, LRRK2 is phosphorylated by other kinases on a num-
ber of residues (i.e. heterophosphorylation). Most interest
has focussed on a series of serines between the ankyrin and
leucine-rich repeat domains that appear to exert a key regu-
latory role on LRRK2. Kinases that have been reported to
phosphorylate these LRRK2 residues are casein kinase 1α
Fig. 2 Rab29-dependent LRRK2 activation model. In the presence of GTP-bound Rab29 the equilibrium between monomeric cytosolic LRRK2 and
kinase-active dimeric membrane-associated LRRK2 is shifted to the membrane form. 1 Monomeric LRRK2 is recruited to TGN membranes by GTP-
bound Rab29. It is not known whether LRRK2 GTP hydrolysis occurs in the cytosol or immediately following membrane recruitment, but the
result is an accumulation of monomeric GDP-bound LRRK2 on TGN membranes. 2 The recruitment of LRRK2 to TGN membranes creates a
microdomain of high LRRK2 concentration, facilitating LRRK2 dimerisation. 3 While dimerised and kinase-active, LRRK2 releases GDP, 4 GTP
exchange occurs, creating dimeric, kinase-active and Rab29-bound LRRK2. 5 Rab29 GTP hydrolysis releases LRRK2 dimers, promoting dissociation
from TGN membranes. 6 Decreased LRRK2 concentration in the cytosol favours monomerisation and kinase inactivation. This last step is impaired
by pathogenic RocCOR mutations. The representation of LRRK2 as LRR, Roc and COR domains is derived from the LRRK2 GTPase cycle proposed
by Deyaert and colleagues, upon which much of this model is built (31).
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(CK1α) [64], the IκB family kinases IKKα, IKKβ, IKKε and
TANK-binding kinase 1 (TBK1) [65], and protein kinase A
(PKA) [66, 67], with dephosphorylation mediated by the
protein phosphatase PP1 [68, 69] and induced by arsenite or
hydrogen peroxide [69]. This range of kinases is perhaps
surprising, since their typical modes of action are notably
different. CK1α is considered a ubiquitous and constitutively
active kinase, so LRRK2 phosphorylation mediated by this
kinase is likely to be modulated only at the level of substrate
availability, rather than by activation or inactivation of the
upstream kinase. By contrast, the IκB family kinases are acti-
vated by a number of cytokines and are especially important
in immune cells, with LRRK2 phosphorylation reported to
be increased following treatment of macrophages with some,
but not all, Toll-like receptor (TLR) agonists, and not by ag-
onists of other immune relevant pathways [65]. Under
physiological conditions, TLRs are activated by pathogens,
forming part of the innate immune response, so these obser-
vations are perhaps more relevant for the role of LRRK2 in
CD, TB and leprosy, although it is worth noting that these
proteins are expressed throughout the brain (in particular in
microglia) [70]. Finally, PKA is well established to be acti-
vated by the second messenger cyclic AMP (cAMP), the
production of which is triggered by a variety of extracellular
ligands and it is likely pertinent to all cell types, not least
neurons. However, PKA-mediated phosphorylation of
LRRK2 has only been reported in cells after treatment with
the pharmacological agent forskolin [67], which activates ad-
enylate cyclase to increase cAMP production, rather than
after treatment with a physiological agonist. As such, the
context under which PKA phosphorylates LRRK2 is not
clear, although this story is supported by reports of an inter-
action between LRRK2 and the PKA regulatory subunit,
RIIβ [71, 72].
What these phosphorylation events have in common,
is their effect on the binding of LRRK2 to 14-3-3 pro-
teins. 14-3-3 proteins are a family of seven highly con-
served proteins that have been reported to bind
hundreds of other proteins (the 14-3-3ζ isoform alone
has over 500 unique interactors listed on BioGRID
[73]). In the majority of cases, 14-3-3 proteins bind spe-
cifically to motifs containing phosphoserine or phos-
phothreonine, and thus protein-protein interactions
involving 14-3-3 proteins are typically phosphorylation
dependent [74]. This is certainly true for LRRK2, which
was first reported to bind all 14-3-3 isoforms other than
14-3-3σ following phosphorylation of two LRRK2 resi-
dues, serine-910 and serine-935 [66, 75, 76]. 14-3-3
proteins have also been reported to bind LRRK2 via
PKA-mediated phosphorylation of a serine residue
(serine-1444) within the LRRK2 Roc domain [67]. The
effect of the LRRK2-14-3-3 interaction is not fully
established, but the evidence, largely from studies using
LRRK2 constructs containing non-phosphorylatable
serine-to-alanine amino acid substitutions at the rele-
vant phosphorylation sites, suggests that 14-3-3 binding
prevents the self-association of LRRK2 into dimers and
perhaps higher order multimers, and thereby affects
both the activity and subcellular localisation of LRRK2
[67, 69, 75]. Much work remains, but this interaction
appears to be of relevance to PD, since co-expression of
14-3-3θ has been reported to rescue the decrease in
neurite outgrowth seen in cultured neurons over-
expressing the pathogenic LRRK2 variants, R1441G or
G2019S [77].
Signalling downstream of LRRK2
Over the years a great deal of work has gone into unco-
vering signalling pathways modulated by LRRK2. Initial
work focussed on MAP kinase pathways, with some evi-
dence found that LRRK2 may affect the activity of all
four classical MAPK pathways: ERK1/2, ERK5, p38
MAPK, and JNK (reviewed by us in [39]). However the
lack of follow-up studies suggest that any role for LRRK2
in these pathways is most likely subtle, for example con-
trolling subcellular localisation of signalling components
via protein-protein interactions, in particular with
MKK3/6/7 and JIPs1-4 [78–80]. Nonetheless, interest in
LRRK2 as a signalling protein has continued and this
protein has been implicated in a variety of pathways, in
addition to those we expand upon below. These also in-
clude, but are not limited to, Akt, Notch and FADD
pathways [81–83].
In light of the relevance of LRRK2 to immune cells, it is
unsurprising that a number of studies have connected this
protein to activation of the transcription factor NF-κB, a
classical mediator of inflammatory responses. However, the
data are not clear cut, on the one hand agreeing that
LRRK2 over-expression stimulates NF-κB activity [84, 85],
while disagreeing on the effect of loss of LRRK2, with de-
creased NF-κB activity reported in Lrrk2 knockdown
microglia [85], but increased activity found in microglia de-
rived from Lrrk2 knockout animals [86]. Impaired NF-κB
activation has been reported in both fibroblasts and iPSC-
derived neurons from individuals carrying pathogenic
LRRK2 mutations [87, 88]. There is clearly more work that
needs to be carried out before a precise role for LRRK2 in
this signalling mechanism can be determined, but two im-
portant observations can be made. First, even though NF-
κB is typically activated by many of the same stimuli that
trigger LRRK2 phosphorylation via IκB family kinases,
LRRK2 does not appear to be required for the activation of
NF-κB by the same TLR ligands that drive LRRK2 phos-
phorylation (i.e. TLR activation and the subsequent activa-
tion of NF-κB and LRRK2 phosphorylation are not part of
a linear pathway). And second, certain data indicate that
LRRK2 may exert an effect on NF-κB via an intriguing
mechanism involving PKA, which in principle puts PKA
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both up and downstream of LRRK2, similarly to Rab29. In
particular, recent data indicate that through an as yet un-
determined mechanism LRRK2 represses phosphodiester-
ase 4, an enzyme responsible for cAMP degradation,
leading to increased PKA activity and enhanced PKA-
mediated phosphorylation of the NF-κB p50 subunit on an
inhibitory phosphorylation site [71, 86]. Although this story
is incomplete it could have relevance for neuronal biology
and in particular PD, since LRRK2 has also been reported
to reduce PKA activity induced by stimulation of the D1
dopamine receptor [72].
A large body of evidence implicates LRRK2 in intra-
cellular calcium signalling. These include observations
of altered mitochondrial and endoplasmic reticulum
calcium signalling in pathogenic LRRK2 neuronal
models [89–92], and roles for LRRK2 in modulating
plasma membrane calcium channels [93, 94]. Given
the well-established roles of calcium at neuronal
synapses, these data suggest pathogenic LRRK2 muta-
tions may affect synaptic physiology at least in part via
an effect on intracellular calcium, which could have
clear relevance to early stages of neurodegeneration in
PD. Importantly, there is already data supporting this
idea ([95, 96]. Furthermore, in addition to endoplas-
mic reticulum and mitochondria calcium signalling,
LRRK2 has been implicated in calcium signalling at ly-
sosomes, the third major intracellular calcium store
[97, 98]. Lysosomes are degradative organelles that
represent the end points of both endocytosis and au-
tophagy, so this story could also be of great potential
relevance to neurodegeneration. Evidence of roles for
LRRK2 in these and other cell biological processes are
summarised below.
Finally, in the context of LRRK2 function in immune
cells, LRRK2 has been implicated in regulating the cal-
cium activated transcription factor NFAT. NFAT is of
central importance to the innate immune response
[99], but also relevant to neuronal biology [100]. Under
basal conditions NFAT is retained in the cytoplasm by
an inhibitory NRON complex, but is activated via
dephosphorylation by the calcium-activated phosphat-
ase calcineurin, which allows NFAT to dissociate from
the NRON complex and enter the nucleus, driving sub-
sequent gene expression. Based on initial observations
made in immune cells from an experimental model of
CD, LRRK2 appears to form part of this complex,
where it strengthens the repression of NFAT [99].
Correspondingly, loss of Lrrk2 potentiates NFAT-
dependent changes in gene expression induced by zy-
mosan, a yeast cell wall component [99]. Since zymosan
acts independently from the TLRs reported to elicit
LRRK2 phosphorylation [65, 99], LRRK2 phosphoryl-
ation by IκB family kinases is unlikely to form part of
this mechanism.
Wnt signalling and GSK3
The connections between LRRK2 and Wnt signalling
pathways, and more generally, signalling mechanisms in-
volving the serine/threonine kinase GSK3β, exist both
up and downstream of LRRK2 and are so broad that we
will address them separately in this section.
Through interactions with multiple Wnt signalling pro-
teins, LRRK2 has been linked to both the canonical/β-catenin
and non-canonical/PCP Wnt signalling pathways [101].
Interactors include the membrane receptor LRP6 [102], key
intermediary proteins such as DVL proteins [103, 104],
Axin1 [102, 105], GSK3β [102, 105–107], PRICKLE1 and
CELSR1 [104], and the canonical Wnt effector β-catenin
[105]. LRRK2 appears to act as a scaffolding protein in these
pathways, potentially exerting effects at multiple stages, such
that over-expressed LRRK2 can cause apparently contradict-
ory effects on β-catenin activation depending on which other
Wnt signalling component it is over-expressed with. None-
theless, the overall consensus is that LRRK2 represses canon-
ical Wnt signalling [104, 105], while activating the non-
canonical/PCP pathway [104]. Since these pathways are usu-
ally mutually antagonistic, this suggests LRRK2 may play a
role in determining the balance between them [101, 104].
Importantly, PD-causing mutations throughout LRRK2 ap-
pear to further repress canonical Wnt signalling [46, 102,
105], although not all publications agree [104], while the pro-
tective LRRK2 variant R1398H has the opposite effect [46].
Given the well-established requirements for Wnt signalling
pathways in the development of the brain and in particular
the dopaminergic neurons of the ventral midbrain that are
typically lost in PD [108], these observations implicate dys-
regulated Wnt signalling as a plausible mechanism under-
lying neurodegeneration caused by LRRK2 mutations.
However, altered canonical and non-canonical Wnt
signalling is not the end of this story. As we describe
below, LRRK2 is connected to microtubule biology via
a number of studies, which include investigations into
phosphorylation of the axonal microtubule-binding
protein Tau [106, 107, 109–111]. Tau phosphoryl-
ation, which causes the detachment of this protein
from microtubules in turn leading to the accumulation
of neurofibrillary tangles and microtubule destabilisa-
tion, is a classical hallmark of Alzheimer’s disease
[112]. Nonetheless, GWAS indicate that Tau is also
highly relevant to PD [113], with post-mortem Tau
pathology having been reported in brains from PD pa-
tients harbouring pathogenic LRRK2 mutations [4,
114, 115] and in LRRK2 mouse models [116–118]. Im-
portantly, studies indicate that LRRK2 promotes Tau
phosphorylation either directly [110], or, perhaps
more plausibly, indirectly, by acting as a scaffold to
enhance Tau phosphorylation by GSK3β, which is very
well described as physiological Tau kinase [106, 107].
This latter mechanism is fascinating, since a suggested
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effect of LRRK2 in canonical Wnt signalling is to pro-
mote the inhibitory phosphorylation of β-catenin,
again via a scaffolding effect on GSK3β [105]. In both
cases, activation of canonical Wnt signalling relieves
this phosphorylation [112]. As such, LRRK2 may con-
tribute to both the Wnt-mediated control of β-catenin
and Tau via a scaffolding action on GSK3β. Both these
events have clear relevance for neurodegeneration.
Taking this one step further, it is fascinating to note
that the inhibitory phosphorylation of NFAT in the
NRON complex is also mediated by GSK3β [99]. Thus,
LRRK2 enhances GSK3β activity via a scaffolding ac-
tion in three distinct protein complexes, and it is
therefore temping to speculate that enhancement of
GSK3β-mediated phosphorylation may turn out to be
a key feature of LRRK2 signalling.
Cell biological functions
Shortly after the discovery of LRRK2, attempts to visual-
ise the distribution of endogenous LRRK2 within the ro-
dent brain using polyclonal antibodies revealed intense
staining across membrane-bound organelles and vesicu-
lar structures, with greatest enrichment across substantia
nigra, thalamus and in particular striatal areas [119,
120]. Although subsequent studies have demonstrated
these antibodies lack specificity [121], work in cellular
models has corroborated the observations, leading to
strong claims of roles for LRRK2 in endocytosis and
autophagy [44, 122–124]. In the rest of this review, and
as summarised in Figure 3, we discuss roles for LRRK2
in these and other cell biological processes where a con-
vincing body of evidence has been established.
Autophagy
Autophagy (from the ancient Greek, “self-eating”) is a
highly specialised mechanism to ensure homeostasis
through degradation of unwanted cellular components.
Three major types of autophagy have been described;
microautophagy, chaperone-mediated autophagy and
macroautophagy [125].
Studies using LRRK2 knockout mice, which curiously dis-
play their most striking phenotype in the kidney [126], leave
little doubt that loss of LRRK2 impacts upon macroauto-
phagy, but shed little light on what role(s) LRRK2 plays in
this process. Within the kidneys of these animals, bi-phasic
age-dependant alterations in macroautophagic activity have
been reported. These organs display increased macroauto-
phagic activity at 7 months, as determined by expression of
the macroautophagy markers LC3-II and p62 and the accu-
mulation of lipofuscin and α-synuclein, and decreased
macroautophagy at 20 months [127]. Increased expression
of lysosomal enzymes, perhaps beginning shortly after birth,
was also reported – an observation that has been confirmed
independently [127–129]. Why loss of LRRK2, a protein
known to mediate profound neurological phenotypes in
humans, manifests in the kidney, is not immediately clear.
Fig. 3 Cell biological processes impacted by LRRK2. As outlined in the main text, LRRK2 has been implicated in regulating processes at
membranous organelles and microtubule-based structures, which are shown in the Figure, as are certain LRRK2-mediated signalling pathways
that are likely to be involved. Although not mentioned in the main text, the nucleus is included as the subsequent organellar target of
transcription factors affected by LRRK2 signalling. The direct interactions between LRRK2 and Rab29, and LRRK2 and microtubules, are depicted
with dashed double-headed arrows. Regulatory mechanisms that are clearly inhibitory to the target are depicted with a round-headed arrow; all
other relationships (whether activatory, too complex to categorise as inhibitory or activatory, or as yet undefined) are depicted with
conventional arrows.
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One possible explanation may lie with the high levels of
LRRK2 in the kidney and the comparatively low levels of
homologous LRRK1, which may fulfil a compensatory role
in other tissues [127]. In support of this hypothesis, gener-
ation of double LRRK knockout mice appear to recapitulate
kidney autophagy defects in the brain [130].
Mechanistic investigations into LRRK2 and macroau-
tophagy performed in cellular models similarly leave lit-
tle doubt that LRRK2 is involved in the process, but
often disagree about what that role might be (reviewed
in [131]). That said, it seems likely that the relationship
is both cell type-specific and complex, with LRRK2 per-
haps modulating early and late steps of the macroauto-
phagy pathway (i.e. macroautophagy induction and
lysosomal function). As judged by levels of the autopha-
gic marker LC3-II, pharmacological inhibition of en-
dogenous LRRK2 kinase activity stimulates autophagy in
H4 neuroglioma cells, SH-SY5Y neuroblastoma cells,
HEK293T cells and primary astrocytes [132–134], but
decreases this process in RAW264.7 macrophages and
BV2 microglia, which are both monocyte cell lines [135].
The knockdown or knockout of LRRK2 also appears to
have differential effects depending on the model used
[133–135]. Furthermore, rapamycin-induced autophagy
causes a higher recruitment of LRRK2 to membrane
fractions containing the autophagic markers LC3-II,
ATG7 and CathepsinD in monocytes, which suggests a
role in mTOR-dependent autophagy [135], whilst
LRRK2 kinase-dependent regulation of LC3-II in H4
neuroglioma cells is independent of mTOR [134]. Re-
garding pathogenic LRRK2 mutations, a number of early
studies report that over-expression of wildtype or mu-
tant LRRK2 induces autophagy [97, 136, 137], yet pri-
mary neurons derived from G2019S knock-in mice show
reduced autophagic activity [116], and human fibroblasts
derived from pathogenic LRRK2 mutation carriers show
a consistent reduction in starvation-induced macroauto-
phagy [138]. When taken together it is fair to conclude
that LRRK2 is very likely involved in macroautophagy,
but clearly further work is required before any consensus
role can be established.
Finally, in addition to regulating macroautophagy,
LRRK2 may itself be a substrate of autophagy, although
in this case, chaperone mediated autophagy (CMA).
CMA is a selective process where protein substrates are
trafficked across the lysosomal membrane via interac-
tions with Heatshock cognate 70, which in turn binds
the lysosomal receptor, LAMP2A [139]. In studies using
both in vitro cell lines and brain slices, treatment with
lysosomal inhibitors caused an increase in intracellular
LRRK2 [140]. Interestingly, the pathogenic LRRK2
G2019S variant was not as efficiently degraded as its
wildtype counterpart whilst overexpression of either
LRRK2 construct was sufficient to inhibit CMA. As
such, the study suggests a mechanism where pathogenic
forms of LRRK2 that are inefficiently turned over by
CMA cause an inhibition of CMA that leads to the accu-
mulation of other CMA substrates [140].
Endocytosis
Several lines of evidence point to LRRK2 as a modula-
tor of endocytosis, including endocytosis of synaptic
vesicles in neurons. Endocytosis is the process of in-
ternalisation of membrane associated proteins via a
series of organellar structures, with the final destination
either being the lysosome for degradation or recycling
into other intracellular locations. Studies linking
LRRK2 and endocytosis include the identification of
LRRK2 as an interacting partner of Rab5b at neuronal
synapses [141]. Rab5 protein acts as a regulator of traf-
ficking and fusion of endocytic vesicles from plasma
membrane to early endosomal compartments, i.e. early
stages of endocytosis [141, 142]. Both depletion and
overexpression of LRRK2 impaired the rate of synaptic
vesicle endocytosis and was rescued by co-expression
with Rab5b [141]. The same group further suggested
Rab5b is directly phosphorylated by LRRK2, causing it
to exhibit stronger GTPase binding activity [143]. Al-
though it is important to note that phosphorylation is
at a different residue to the conserved phosphorylation
site in other Rab proteins, others studies do not support
Rab5b as a LRRK2 substrate [35]. In any case, the use
of a phosphomimetic Rab5b mutant indicated that
Rab5b phosphorylation acts as a negative regulator of
neurite outgrowth. This could also be relevant beyond
neuronal cells, as this construct also impaired EGF re-
ceptor (EGFR) degradation in HeLa cells [143], which is
consistent with slower endocytosis.
In contrast to Rab5 proteins, Rab7 acts at later stages in
endocytosis, including at lysosomes. Rab7 has been con-
nected to LRRK2 in a small number of papers, the first be-
ing a report of a physical interaction between these
proteins in Drosophila [144]. Rates of endocytosis were not
investigated, although an effect on lysosomal positioning
was reported [144]. Nonetheless, two subsequent papers in-
dicate that LRRK2, and to a greater extent, pathogenic
forms of LRRK2, slow EGFR degradation by impairing later
stages of endocytosis and that Rab7 is involved in this
process [145, 146]. Together these studies find a fascinating
regulatory model where LRRK2-mediated phosphorylation
of Rab8A leads (through an as yet undefined mechanism)
to decreased Rab7 activity, which leads to EGFRs failing to
traffic to lysosomes and instead accumulating in a Rab4-
containing vesicular compartment [146]. The consequences
of delayed endocytosis in this context have not been estab-
lished, but since receptor internalisation is intrinsically
linked to strength and duration of signalling pathway
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activation [39], this could have implications for cascades
relevant to cell survival.
Returning to endocytosis in neurons, down-
regulation of synaptic vesicle endocytosis in the ab-
sence of LRRK2 has also been corroborated in a
number of studies [95, 147–150]. For example,
LRRK2 knockdown in cortical neurons caused redis-
tribution of synaptic vesicles to the recycling pool
and fewer docked vesicles in contact with the pre-
synaptic membrane [95]. Furthermore, several of these
findings have been replicated following treatment of
wildtype neurons with LRRK2 inhibitors, suggesting a
kinase-dependent mechanism [147].
One suggested mechanism of action is EndophilinA
phosphorylation [148, 149, 151]. Similarly to several mem-
brane associated proteins, EndophilinA contains a BAR
domain that is believed to modulate membrane curvature
and vesicle release. In the first of these papers the authors
reported that phosphorylation of the Endophilin A BAR
domain by LRRK2 hampers its ability to dissociate from
membranes causing membrane deformation and impaired
synaptic vesicle endocytosis at Drosophila neuromuscular
junctions [148]. Fascinatingly, both hyperphosphorylation
elicited by over-expression of the LRRK2 G2019S variant
or loss of basal EndophilinA phosphorylation following
knockout of the Drosophila LRRK2 orthologue caused a
similar impairment of synaptic vesicle endocytosis [148].
These data suggest a requirement for tight regulation of
EndophilinA phosphorylation for normal neuronal func-
tioning, and are also consistent with the previous observa-
tion of impairments in synaptic vesicle endocytosis
following knockout or overexpression of LRRK2 [141]. In
a further twist, LRRK2-dependent EndophilinA phosphor-
ylation has also been implicated in neuronal autophagy,
with phosphorylated EndophilinA reported to recruit the
autophagic factor Atg3 during induced autophagosome
formation [151]. The relevance of EndophilinA phosphor-
ylation to mammals remains to be established, although
LRRK2 can phosphorylate human EndophilinA proteins
in vitro [149]. Nonetheless EndophilinA phosphorylation
is an interesting story to follow.
LRRK2 has also been implicated in other synaptic ves-
icular trafficking processes and in behavioural phenotypes
that are consistent with altered synaptic properties, al-
though these studies have produced a range of results,
perhaps a consequence of the different neuronal popula-
tions and models studied. Overexpression of wildtype
LRRK2 in BAC-transgenic mice showed elevated release
of striatal dopamine, whereas G2019S mice showed an
age-dependent decrease in striatal dopamine uptake, re-
lease and content [152]. A separate study further reported
D2-receptor mediated short-term plasticity defects in stri-
atal glutamate neurons of mice overexpressing wildtype
LRRK2 [153]. Interestingly, no synaptic abnormalities have
been reported in the striatum of LRRK2 knockout mice
[153]. Behavioural analysis of wildtype LRRK2 overexpres-
sion models has yielded conflicting results with reports of
both hyperactivity and enhanced motor performance and
hypoactivity and memory impairments [152, 153]. Overex-
pression of G2019S-LRRK2 has been shown to cause
deficits in long term depression and age-dependent dys-
functional plasticity in the hippocampus [154].
Fascinatingly, LRRK2 is linked to neuronal endocytic
events involving proteins encoded by genes implicated in
autosomal recessive early-onset parkinsonism: SYNJ1
[155, 156] and DNAJC6 [157]. SYNJ1 encodes for the
synaptically enriched lipid phosphatase Synaptojanin1
which functions in the uncoating of neuronal vesicles.
Similarly, the neuronal specific protein Auxillin, encoded
by DNAJC6, acts as a co-chaperone with Hsc70 to uncoat
clathrin vesicles [158]. Intriguingly, both of these proteins
have recently been nominated as direct targets of LRRK2
phosphorylation [150, 159]. Elevated synaptojanin1 phos-
phorylation was first observed in Drosophila modified to
express human R1441C [160]. The direct phosphorylation
of synaptojanin1 by LRRK2 was subsequently demon-
strated in vitro and shown to impair interactions with
endophilinA [150]. LRRK2 phosphorylation of auxilin was
similarly found to disrupt interactions with clathrin,
resulting in endocytic defects and decreased synaptic vesi-
cles in patient-derived iPSC dopaminergic neurons [159].
These results await independent replication but the fact
these three PD-related genes – LRRK2, SYNJ1 and
DNAJC6 – might act in a common pathway is clearly in-
triguing. Moreover, these observations form part of a
wider body of data connecting PD with endocytosis and
membrane trafficking processes more generally, for ex-
ample reviewed by [161]. The strength of this connection
is underscored by recent evidence that genes encoding
endocytosis proteins contribute significantly to the poly-
genic risk of PD [162].
Lastly, it is worth stressing that both autophagy and
endocytosis terminate in lysosomes, which strongly sug-
gests these two processes impinge upon each other.
With this in mind we note a recent study describing an
intersection of LRRK2 with both upstream and down-
stream Rabs at lysosomes [124]. Treatment of cells with
the lysosomal stressor chloroquine induced LRRK2 re-
cruitment onto enlarged lysosomes with co-expression
of Rab29 facilitating this phenotype. Overexpression
screening of 27 different Rab GTPases revealed the
LRRK2 substrates Rab8a and Rab10 colocalising with
LRRK2-positive lysosomes under stressed conditions in
a LRRK2 kinase dependent manner [124]. Interestingly,
Rab29 activation of LRRK2 reduced stress-associated
lysosomal enlargement and upregulated lysosomal secre-
tion, whereas Rab8a suppressed enlargement and Rab10
promoted secretion. Taken together, these observations
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support a model whereby Rab29, LRRK2 and its Rab
substrates participate in lysosomal homeostasis [124].
Trans-Golgi Network
Evidence connecting LRRK2 to Rab29 has also linked
LRRK2 to a category of organelle that is not directly part
of the endocytic or autophagic pathways: the trans-Golgi
network (TGN). In the first of these publications, over-
expression of the pathogenic G2019S variant was found
to phenocopy Rab29 knockdown in significantly redu-
cing mannose 6-phosphate receptor (MPR) localisation
at the Golgi [41]. These were fascinating observations,
since reduced MPR localisation at the TGN is a well de-
scribed consequence of loss of retromer complex func-
tion [163]. The retromer complex mediates recycling of
transmembrane receptors from endosomes towards the
TGN, and a key component of this complex is VPS35.
Remarkably, like LRRK2 and RAB29 variants, VPS35 mu-
tations are a cause of PD [164, 165], and in agreement, a
PD-associated VPS35 variant, D620N, elicited a similar
effect on MPR localisation [41]. The authors reported
that LRRK2 physically interacts with VPS35, whilst over-
expression of wildtype VPS35 rescues defects caused by
mutant LRRK2 or Rab29 knockdown. Thus, their data
suggests LRRK2 acts as a modifier of VPS35 function in
recycling of proteins and membranes from the endoso-
mal system to the TGN [41].
As mentioned, the second paper linking LRRK2 to
Rab29 did so as part of a screen for LRRK2-interacting
proteins, which also identified BCL2-associated athano-
gene 5 (BAG5) and Cyclin-G–associated kinase (GAK)
as interactors [42]. In the context of PD, BAG5 and
GAK are interesting proteins. GAK has been identified
previously as candidate risk loci for sporadic PD by
GWAS [41, 42], whereas BAG5 has been reported to
promote degeneration of dopaminergic neurons through
inhibition of the E3 ubiquitin ligase Parkin, which causes
recessive PD [166, 167]. LRRK2, GAK, BAG5 and Rab29
were found to form a single complex revealed by fluores-
cence cell imaging to localise to the TGN where they
promote a Golgi clustering phenotype [42]. Golgi clus-
tering was enhanced by all known pathogenic variants of
LRRK2, and the clustering induced by the overexpres-
sion of anyone of the four proteins could be at least par-
tially rescued by knockdown of any one of the other
three proteins. Fascinatingly, Golgi clustering appeared
to require autophagy, as the effect of LRRK2 overexpres-
sion could also be rescued by inhibition of lysosomal
acidification or knockdown of the key autophagy protein
Atg7 [42]. As such, both studies demonstrated a physical
interaction between Rab29 and LRRK2 that is of func-
tional relevance to the Golgi, and in particular TGN, yet
they differ regarding the effects of Rab29 manipulation.
Some of these differences can be ascribed to the
different experiments performed, yet both studies per-
formed comparable neurite outgrowth assays. Confus-
ingly, Beilina et al. find that knockdown of Rab29
rescues the decreased neurite outgrowth caused by
LRRK2 overexpression and overexpression of Rab29 rep-
licates the phenotype [42], whereas MacLeod et al. re-
port that decreased neurite outgrowth elicited by
LRRK2-G2019S is rescued by overexpression of Rab29
and replicated by Rab29 knockdown [41]. As such, the
two papers disagree entirely on whether greater Rab29
activity is beneficial or detrimental to cells.
Subsequent findings favour the idea that elevated
Rab29 activity is cytotoxic. Notably, Rab29 recruitment
of LRRK2 to the TGN enhances LRRK2 kinase activity
[43, 44]. Since increased LRRK2 kinase activity appears
to be a close correlate of LRRK2 pathogenicity, this is
clearly consistent with Rab29 activity being detrimental
to cells. Importantly, the clustered Golgi phenotype ob-
served following LRRK2-Rab29 colocalisation has been
replicated [43, 44]. This exciting story is still evolving,
but additional details include roles for CK1α and
guanosine-nucleotide exchange factor, ARHGEF7 in
regulating recruitment of LRRK2 to the TGN [64]. As
mentioned above (see also Fig. 1), CK1α is a kinase re-
sponsible for constitutive phosphorylation of LRRK2
[64], whereas ARHGEF7 has previously been reported to
modulate LRRK2 GTPase activity [51].
Mitochondria
The mitochondria – organelles responsible for cellular
respiration and energy production – are heavily implicated
in PD, with numerous lines of evidence demonstrating
that mitochondrial dysfunction is part of the pathology of
idiopathic PD and certain types of familial PD. Most not-
ably, decreased mitochondrial complex 1 activity in the
substantiae nigrae of PD patients is a well-established
phenomenon [168], and a number of environmental
toxins that cause nigral legions and parkinsonian pheno-
types in humans and animal models are inhibitors of this
aspect of mitochondrial function [169–171]. Furthermore,
proteins encoded by several genes associated with early-
onset forms of familial PD, such as PINK1 and Parkin,
function within a common evolutionarily conserved path-
way responsible for removing dysfunctional mitochondria
by mitophagy (reviewed by others, e.g. [172, 173]). Loss of
these proteins causes an accumulation of larger mitochon-
dria, decreased ATP production and increased levels of re-
active oxygen species, leading to a selective loss of
dopaminergic neurons of the substantia nigra. It is worth
noting that since the cell loss caused by PINK1 or Parkin
mutations is so selective and not usually accompanied by
Lewy body formation they may not represent a true form
of PD but ‘nigral mitochondrial cytopathies’ [174]. In any
case, it is evident that the group of dopaminergic neurons
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lost specifically in PD are especially sensitive to mitochon-
drial dysfunction, so any implication of LRRK2 in mito-
chondrial biology is of great interest.
When taken together, the evidence that pathogenic
LRRK2 variants cause an impairment in mitochondrial
function is very strong. For example, in Drosophila and
transgenic mice, the G2019S LRRK2 variant has been
shown to impart an increased sensitivity to mitochon-
drial toxins [175, 176], with a similar response reported
in dopaminergic neurons derived from LRRK2 mutation
carriers [177, 178]. Nonetheless, it remains to be estab-
lished whether pathogenic forms of LRRK2 cause an
underlying defect in mitochondrial function that makes
these organelles more sensitive to toxins, or whether
LRRK2 mutants reduce the cell’s ability to cope with
damaged mitochondria. These mechanisms are not mu-
tually exclusive and there is data supporting either possi-
bility. For example, LRRK2 G2019S is reported to
increase phosphorylation of peroxiredoxin-3 (PRDX3), a
scavenger of hydrogen peroxide produced by mitochon-
dria, causing inhibition of endogenous peroxidases [179,
180]. But on the other hand, a detailed study of primary
human fibroblasts from both manifesting and non-
manifesting LRRK2 mutation carriers, revealed a convin-
cing preclinical impairment in the activities of mito-
chondrial complexes III and IV [181]. Supporting this
interpretation further, a number of studies report that
LRRK2 mutations elicit abnormalities in mitochondrial
morphology – in particular mitochondrial fragmentation
[182–184].
It is interesting to note that this weight of evidence
linking LRRK2 and mitochondria functionally is not
matched by a corresponding amount of data supporting
a physical interaction. Early investigations did report
LRRK2 localisation on mitochondrial membranes [119,
185], but these observations have not been replicated to
the extent that might be expected. As such, any associ-
ation between LRRK2 and this organelle is most likely
transient and/or context specific. In agreement with
this, there is evidence that wildtype LRRK2 is recruited
to the mitochondrial outer membrane in human iPSC-
derived neurons treated with the mitochondrial
depolarising agents Antimycin A and CCCP [186].
Therefore, if LRRK2 is not permanently located on
mitochondria, how might pathogenic LRRK2 mutations
cause defects in mitochondrial morphology and respir-
ation? One possibility is via altered mitochondrial bio-
genesis [182], nonetheless we note that the reported
recruitment of LRRK2 to the mitochondrial outer
membrane induced by mitochondrial depolarisation in-
volves a physical interaction between LRRK2 and a pro-
tein called Miro [186]. Miro is an outer mitochondrial
membrane protein that acts as a tether, attaching
mitochondria to microtubule motor proteins, thereby
facilitating the transport of mitochondria along micro-
tubules. The authors further reported that the binding
of LRRK2 to Miro triggers transport of damaged mito-
chondria along axonal microtubules, leading to their re-
moval by mitophagy (a type of macroautophagy that is
selective for damaged mitochondria) [186]. Fascinat-
ingly, this response is lost in cells expressing LRRK2
G2019S, as this pathogenic variant is not recruited to
Miro by mitochondrial depolarisation [186]. The result
of this is a reduction in the removal of damaged mito-
chondria by mitophagy. Intriguingly, these observations
are consistent with independent studies reporting that
pathogenic LRRK2 RocCOR domain mutations also
elicit decreased rates of microtubule-based mitochon-
drial trafficking in axons [187](188]. Since LRRK2 is
heavily linked to microtubules, we return to these cyto-
skeletal structures later in this article. Nonetheless,
these are exciting observations, suggesting a pathome-
chanism at the crossroads of three important aspects of
LRRK2 biology: microtubules, macroautophagy and
mitochondria.
Endoplasmic reticulum
Another intracellular organelle to which LRRK2 has
been linked is the Endoplasmic reticulum (ER). This or-
ganelle is responsible for the translation, folding and
trafficking of newly synthesised membrane and secreted
proteins, and is also the major store of intracellular cal-
cium. In the event of protein misfolding, the accumula-
tion of misfolded proteins within the ER lumen can
trigger a stress response that halts protein translation
and activates signalling pathways to increase production
of molecular chaperones [189]. An elevated ER stress re-
sponse is well described in PD brains and may represent
a protective mechanism to restore protein homeostasis
[190]. Given the range of processes linked to LRRK2 it is
perhaps unsurprising that LRRK2 has been implicated in
ER stress responses, first indirectly, via the localisation
of LRRK2 to the ER of intact dopaminergic neurons in
healthy and PD brain tissue [191], and also directly, as
part of a possible protective mechanism [192]. In par-
ticular, LRRK2 expression was found to be required for
the full upregulation of GRP78, an ER chaperone pro-
tein, in SH-SY5Y cells treated with the ER stress indu-
cing agent tunicamycin, an observation that correlated
with increased cell death. Suggesting this may be of rele-
vance to neurodegeneration, a similar requirement for
LRRK2 was found for the induction of GRP78 expres-
sion and cell survival in response to the neurotoxin 6-
hydroxydopamine [192]. This story is in its infancy, but
it is interesting to note that the authors also found a
similar effect on the resistance of dopaminergic neurons
to 6-hydroxydopamine in nematodes lacking the LRRK2
ortholog, and provide evidence that similar mechanisms
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may operate in response to treatment with human α-
synuclein [192].
In addition, LRRK2-mediated anterograde trafficking
of vesicles from the ER to the Golgi has been described.
This study found that LRRK2 selectively recruits Sec16A
to the ER where it forms vesicle exit sites. As such,
LRRK2 knockdown disrupted the association of Sec16
with exit sites and the transport of vesicles to the Golgi.
Similarly, knock-in of the pathogenic LRRK2 variant
R1441C weakened interaction with Sec16 leading to im-
pairments of ER vesicle release [193].
Ribosomes and translational control
LRRK2 has long been implicated in translational control
via the direct phosphorylation of the protein synthesis
machinery. This story began with a report that
eukaryotic initiation factor 4E binding protein (4E-BP), a
repressor of translation, is a substrate of the Drosophila
LRRK2 homologue dlrrk [194]. This phosphorylation
event was reported to inactivate 4E-BP thereby promot-
ing cap-dependent protein synthesis, with prolonged
phosphorylation leading to deregulated bulk protein
translation [194]. Perhaps consistent with this, an inde-
pendent study also using Drosophila reported an effect
of postsynaptic expression of LRRK2 transgenes on pre-
synaptic neurotransmitter release that can be blocked
with protein synthesis inhibition [195]. However, other
studies indicate that phosphorylation of 4E-BP by
LRRK2 does not happen in mammalian systems. In par-
ticular, LRRK2 does not alter the phosphorylation of the
human 4E-BP homologue in cells [196–198], and only
phosphorylates this protein to a very low stoichiometry
in vitro [197]. Nonetheless, LRRK2 has been reported to
phosphorylate three human ribosomal proteins in vitro
– S11, S15, and S27 – albeit also at low stoichiometry,
but with S15 phosphorylation also observed in both
mammalian neurons and Drosophila [198]. This paper
produced two observations that are pertinent here. First,
the authors were unable to demonstrate an effect of
LRRK2 on 4E-BP phosphorylation in Drosophila, but
were able to replicate the positive effect of LRRK2 on
protein synthesis and extend this observation to mam-
malian neurons, although in this case the increase in-
volved both cap-dependent and cap-independent
translation [198]. And second, overexpression of a
phosphodeficient S15 mutant protein (i.e. S15 with the
LRRK2 phosphorylation site mutated to alanine) re-
duced the toxicity induced by pathogenic LRRK2 vari-
ants in Drosophila, rat and human neuronal systems
[198]. Taken together, these studies suggest that 4E-BP
most likely is not a LRRK2 substrate, but indicate that
LRRK2 may yet exert a positive effect on protein syn-
thesis in Drosophila. Whether this proves to be repro-
ducible in mammals – and whether this involves
phosphorylation of ribosomal proteins – remains to be
seen, but given its potential importance, follow-up
studies are eagerly awaited.
In addition to the above, LRRK2 is also reported to affect
Drosophila gene expression at the post-transcriptional level
via effects on microRNAs (miRNAs). miRNAs are consid-
ered to prevent translation by binding to mRNA molecules
and blocking protein synthesis, while also destabilising the
mRNA. In particular, LRRK2 was found to interact with
Argonaute (Ago1), a component of the miRNA pathway
[199]. In the brains of aged Drosophila, pathogenic human
LRRK2 variants caused a down-regulation of dAgo1, which
in turn led to a suppression of the activity of two miRNAs,
let-7 and miR-184, and a corresponding increase in the
translation of two target genes, DP1 and E2F1 [199]. Since
DP1 and E2F1 are involved in the cell cycle, this suggested
a potential pathomechanism whereby LRRK2 elicits overex-
pression of these proteins, which are likely toxic to post-
mitotic neurons. Consistently, overexpression of either
miRNA rescued the effect of overexpressed pathogenic
LRRK2 variants on dopaminergic cell death, while partial
loss of DP1 or E2F1 had similar effects [199]. Although this
is a single study, the proposed mechanism via Ago1 creates
the possibility that LRRK2 might alter the expression of
multiple different miRNAs in different systems, so this is an
intriguing story.
Microtubule binding and cytoskeletal dynamics
In addition to cell biological processes involving
membranous organelles, LRRK2 is strongly linked to
the cytoskeleton, and in particular, microtubules. Mi-
crotubules are ubiquitous multimeric protein scaffolds
that are central to many cellular structures and
underpin a range of key cellular processes. As we
outline in this section, LRRK2 has been implicated in
a number of these: neurite outgrowth, trafficking of
membranous cargo along axons, and the formation of
cilia and centrosomes. Indeed, the inhibitory effect of
LRRK2 overexpression on neurite outgrowth, which is
potentiated by pathogenic mutations and has been
replicated in multiple studies, is likely underpinned, at
least in part, by binding of LRRK2 to microtubules
(reviewed by ourselves elsewhere [200, 201]).
Interactions between LRRK2 and microtubules were
first described in 2006 [119, 202], with binding eventu-
ally shown to be direct and specific to three β-tubulin
isoforms, TUBB, TUBB4 and TUBB6 [61]. β-tubulins as-
sociate with related α-tubulins and the resulting hetero-
dimers assemble into the long tubular structures that
comprise microtubules. The LRRK2 binding site in β-
tubulins was mapped to residues that are proximal to
the binding site for the microtubule stabilising drug
Taxol [61]. This suggested that LRRK2 binding may in-
fluence microtubule stability and consistently, LRRK2
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knockout MEF cells displayed a significant increase in
microtubule acetylation – a post-translational modifica-
tion known to induce microtubule stability [203] – with
similar observations subsequently made in the LRRK2
knockout mouse kidney [61, 129]. In addition, LRRK2
displayed a stronger localisation to microtubules in
neuronal growth cones compared to those in adjacent
axons, indicating a preferential binding to dynamic, i.e.
not acetylated and stabilised, microtubules [61]. This
prediction was confirmed in an independent study
reporting that treatment of cells with deacetylase inhibi-
tors or the tubulin acetylase αTAT1, both of which can
be expected to increase tubulin acetylation, reduce the
association of wildtype and pathogenic forms of LRRK2
with microtubule structures [187]. Fascinatingly, this lat-
ter study not only reported a stronger association be-
tween acetylated microtubules and the pathogenic
LRRK2 RocCOR variants R1441C and Y1699C, but also,
as mentioned above, found that these variants caused
decreased transport of mitochondria along axonal mi-
crotubules in cortical neurons [187]. Perhaps surpris-
ingly, the G2019S kinase domain mutant did not exert
the same effect, suggesting this phenotype may be
specific for LRRK2 GTPase mutations. Nonetheless,
these observations of impaired mitochondrial trafficking
underscore a key effect of altered microtubule function:
disruption of microtubule-dependent organelle and
vesicle transport. Disrupted trafficking of these mem-
branous structures can cause subsequent deficits in pro-
cesses they mediate (e.g. endocytosis, autophagy etc) and
illustrate how microtubule integrity is vital for normal
healthy cells.
Following the recent identification of Rab GTPase
phosphorylation by LRRK2 [34], several groups have in-
vestigated downstream effects of elevated Rab protein
phosphorylation, a path that has ultimately led to cell
biological processes with microtubules at their core. In
the first of such studies, phosphorylated forms of Rab8a
and Rab10 were found to bind preferentially to two re-
lated proteins, Rab interacting lysosomal protein like 1
and 2 (RILPL1 and RILPL2) [35]. Rab8A, Rab10 and
RILPL1/2 have all previously been reported to regulate
primary ciliogenesis (i.e. the generation of primary cilia),
suggesting that LRRK2 might also modulate this process.
Primary cilia are microtubular projections emanating
from the cell surface of numerous mammalian cell types
and are considered key regulators of many signalling
pathways. Fascinatingly, these include a number of cas-
cades relevant to LRRK2, including Wnt and calcium
signalling [204]. In any case, a role for LRRK2 in regulat-
ing ciliogenesis was confirmed as fibroblasts derived
from knock-in mice carrying the pathogenic R1441G
LRRK2 mutation displayed reduced starvation-induced
cilia formation [35]. In subsequent work, cilia defects
were also observed in fibroblasts and iPSCs derived from
G2019S carriers, as well as striatal cholinergic neurons
from a LRRK2 R1441C mouse model, demonstrating
that multiple pathogenic LRRK2 mutations can impact
on cilia formation. Critically, LRRK2 kinase inhibition
was able to rescue defects caused by pathogenic LRRK2
both on cilia formation and cilia-dependent Sonic
Hedgehog (Shh) signalling [205]. As such, the authors
suggest mutant LRRK2 causes loss of cilia that may dis-
rupt the ability of dopaminergic neurons to respond to
neuroprotective Shh signals – an intriguing explanation
of nigral legions in LRRK2-PD. The authors also re-
ported that LRRK2 impairs ciliogenesis via the phos-
phorylation of Rab10 and not of Rab8a; fascinatingly,
they found Rab8a and Rab10 to have opposing effects on
cilia formation [205]. As such, it is plausible that LRRK2
might enhance ciliogenesis in cells where expression of
Rab8a is high compared to that of Rab10.
The second microtubular structure linked to LRRK2 by
Rab protein phosphorylation is the centrosome. Centro-
somes are the primary microtubule organising centre in
most cells, and are central to determining cell shape and
polarity, as well as the positioning of spindle poles during
mitosis. Perhaps very pertinently, centrosomes are structur-
ally similar to cilia [206]. Two recent publications from
Sabine Hilfiker’s laboratory link LRRK2 phosphorylation of
Rab8a to centrosomal deficits [36, 207]. In the first paper,
defects in centrosomal positioning and migration that were
induced only by pathogenic LRRK2 variants and not wild-
type LRRK2 were closely associated with an accumulation
of pericentrosomal phosphorylated Rab8a [36]. This pheno-
type was rescued by expression of a non-phosphorylatable
Rab8a mutant or by depletion of endogenous Rab8a. Intri-
guingly, a split centrosome phenotype was also observed
within fibroblasts derived from LRRK2-G2019S carriers
which was reversed by LRRK2-kinase inhibitors [36]. The
second paper found that when recruited to the TGN by
overexpressed Rab29, wildtype LRRK2 was able to induce
the same phenotype via enhanced Rab8a phosphorylation
[207]. Fascinatingly, whilst wildtype LRRK2 required both
Rab29 and Golgi integrity to elicit this effect, pathogenic
forms did not, indicating that activation of wildtype LRRK2
by Rab29 on TGN membranes may be a physiological
mechanism that PD-causing variants are able to by-pass.
Integrating the information: implications for PD
Since the discovery of LRRK2 mutations as a cause of
PD that is clinically indistinguishable from idiopathic
PD, it has been hoped that mutant LRRK2 pathome-
chanisms will shed light on PD and perhaps create
therapeutic targets to stop this condition at its earliest
stages. As such, how the perturbed cell biological pro-
cesses, that we have outlined above, might ultimately
elicit neurodegeneration is perhaps the most important
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question remaining. This review summarises the basic
biochemistry and cell biology of LRRK2, so a detailed
commentary is clearly beyond the scope, but in this sec-
tion, we nonetheless attempt to extract some pertinent
observations from the mass of data. We would not ex-
pect these observations to guide future studies – our
colleagues working on more translatable areas of LRRK2
research are well ahead of us here – but at the least we
hope to provide some sort of context and direction for
the reader.
So, which of the organelles and cell biological pro-
cesses impacted by LRRK2 are most relevant? Let’s
start from first principles. PD is ultimately a disease
that is caused by dopaminergic cell death and is ac-
companied by the formation of Lewy bodies. There-
fore, the most relevant effects of LRRK2 mutations
are clearly those that most easily account for these
phenomena. Similarly, using an Ockham’s razor type
of ‘simplest is most likely’ principle, we would also
expect pathogenic LRRK2 mutations to act in a com-
mon mechanism with PD-causing mutations in other
loci. With this in mind, it is worth highlighting re-
search into the molecular mechanisms by which GBA
mutations elicit a similar type of late-onset PD to
LRRK2 (and indeed, to idiopathic PD). In particular,
loss-of-function GBA mutations are now well estab-
lished to cause lysosomal dysfunction, leading to im-
paired autophagic clearance of α-synuclein and a
positive feedback loop where elevated α-synuclein
causes a further impairment of lysosomal function
[208]. Pathogenic mutations in ATP12A2 appear to
operate via a similar mechanism [208]. As such, im-
paired lysosomal function seems sufficient to account
for the formation of Lewy bodies, which are primarily
composed of α-synuclein.
As we have described, LRRK2 is connected to lyso-
somal biology via a number of mechanisms including
endocytosis and autophagy, which both terminate with
fusion of vesicular structures to lysosomes, and also in
some reports to lysosomal function itself [97, 98, 124].
Importantly, this includes interactions with its up-
stream activator and fellow PD risk gene product,
Rab29 [124]. The implications for endocytosis are im-
portant here, since this process is linked to polygenic
risk of PD [162], as well as other PD-related genes
such as DNAJC6 and SYNJ1 [155–157]. Nonetheless,
impaired lysosomal function would also lead to an in-
evitable and potentially rapid increase in faulty mito-
chondria, as these organelles are cleared by mitophagy
as part of their normal homeostasis [209]. Pathogenic
LRRK2 mutations impairing normal lysosomal func-
tion could therefore not only account for elevated
levels of α-synuclein and hence Lewy bodies, but also
the mitochondrial dysfunction and increased levels of
reactive oxygen species that are frequently observed in
neurodegeneration.
If LRRK2 mutations cause cell death via lysosomal dys-
function, why would they affect the dopaminergic neurons
of the substantia nigra in particular? There are many theor-
ies as to why this group of neurons are specifically lost in
PD, but a curious feature of dopaminergic neurons of the
substantia nigra is the length of their axons, which are
amongst the longest of any CNS neuron. By virtue of their
length, these neurons are especially sensitive to disruptions
in the trafficking of organelles and vesicles over long dis-
tances. With this in mind, it is important to stress the im-
portance of microtubules for vesicular and organellar
transport. The positioning of membranous organelles is
largely dictated by the cytoskeleton in all cell types, and
vesicle transport along microtubules is a similarly ubiqui-
tous phenomenon. But in neurons, axonal microtubules be-
have like veritable motorways, allowing communication
and transport of materials between the cell body and dis-
tant growth cones [200]. We are clearly at the point of
speculation, but if the key effect of LRRK2 mutations were
to be impairments in microtubule-based endolysosomal
trafficking in axons, this could in a single mechanism ac-
count for lysosomal dysfunction and the ensuing effects on
α-synuclein levels and mitochondria, and the selective in-
volvement of dopaminergic neurons. Moreover, such a
mechanism would also begin to reconcile the implication in
PD from GWAS of the axonal microtubule interacting pro-
tein Tau [7], and might go some way to explaining the vari-
ous signal transduction abnormalities associated with
LRRK2. In the majority of cases, activated membrane re-
ceptors are trafficked through the endosomal system to ly-
sosomes, where their signals are terminated. Manipulations
that slow retrograde endosomal flux thereby increase signal
duration in most pathways, although curiously, in the case
of canonical Wnt signalling, where sequestration of GSK3
into late endolysosomal compartments is a key step in the
activation of β-catenin, delayed trafficking of receptor sig-
nalosomes decreases signalling [210]. As mentioned, dopa-
minergic neurons of the ventral midbrain have a special
requirement for canonical Wnt signalling in their develop-
ment, and numerous lines of evidence suggest this require-
ment continues into adulthood [211, 212].
Our proposed mechanism is clearly not without limitations
and we do not claim to have all the answers. For example, a
primary deficit affecting lysosomes or late endolysosomal
trafficking is not immediately reconcilable with the strong
story building around LRRK2, Rab29 and the trans-Golgi
network. Nonetheless, there is strong evidence that enhan-
cing lysosomal function is strongly neuroprotective in animal
PD models (e.g. [213, 214]). As such, targeting these pro-
cesses seems a viable approach for reducing neurodegenera-
tion in general, even if it does not turn out to be the best
approach for targeting LRRK2 PD in particular.
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Conclusions
In many regards the LRRK2 field is the same as it has al-
ways been: complex. This protein remains at the centre
of more pathways, processes and diseases than seems
possible. Although breakthroughs are made, they just
seem to take us back to the same place, generating even
more questions. For example, in 2013 we observed that
the most published facet of LRRK2 biology was interac-
tions with microtubules [215] and the long sought after
identification of Rab proteins as bona fide LRRK2 sub-
strates in 2016 [34] has pointed us to two microtubular
structures: centrosomes and cilia. Plus ça change, plus
c’est la même chose. The LRRK2 field does not seem to
evolve, it just seems to get bigger.
And yet the field is moving forward. Advances in
structural biochemistry are taking us closer to an
understanding of the structure of LRRK2 and its
GTPase activity. The similarities between some of
the inflammatory diseases in which LRRK2 has been
implicated will likely foster advances in understand-
ing the function of LRRK2 in immune responses –
although whether PD is an inflammatory condition
remains another story. And the identification of
Rab29 as an activator of LRRK2 kinase will surely be
a great boon to the LRRK2 community, expediting
research into the pathological consequences of
LRRK2 mutations, and perhaps leading to the
identification of further LRRK2 substrates. Whether
LRRK2 pathology turns out to be through altered
cell signalling, perturbed organellar processes or im-
paired microtubule function – or indeed, a combin-
ation thereof – we will get there.
We also note the recent report that vitamin B12 is a
‘mixed-type allosteric inhibitor’ of LRRK2 kinase activity;
that is, vitamin B12 does not compete with ATP for the ac-
tive site of the LRRK2 kinase domain, as is the case for all
other LRRK2 kinase inhibitors, but binds elsewhere to in-
duce a conformational change [216]. Fascinatingly, vitamin
B12 appears to promote the monomerisation of LRRK2,
opening the door to an alternative therapeutic approach.
This is potentially important, since there is evidence that
conventional LRRK2 kinase inhibitors reverse the effects of
pathogenic RocCOR mutations on substrate phosphoryl-
ation, but potentially mimic these mutations in other
regards (e.g. increased LRRK2-GTP binding [64, 217], in-
creased association with filamentous microtubular struc-
tures [217], and impaired Wnt signalling [102, 105]). The
results of on-going clinical trials are therefore eagerly
awaited. But in any case, when allied with conventional kin-
ase inhibitors and guanine nucleotide binding inhibitors,
vitamin B12 forms part of a tool kit to modulate LRRK2
function pharmacologically in three distinct ways. It is an-
other small step towards understanding this most mysteri-
ous of proteins. These are exciting times.
Abbreviations
4E-BP: Eukaryotic initiation factor 4E binding protein; ANK: Ankyrin repeats;
ARM: Armadillo repeats; BAG5: BCL2-associated athanogene 5; cAMP: Cyclic
AMP; CD: Crohn’s disease; CK1α: Casein kinase 1α; CMA: Chaperone
mediated autophagy; COR: C-terminal of roc; DVL: Dishevelled; GAD: GTPase
Activated by Dimerisation; GAK: Cyclin-G–associated kinase; GAP: Guanine
activating proteins; GWAS: Genome-wide association studies;
Hsc70: Heatshock cognate 70; LRR: Leucine rich repeats; NFAT: Nuclear factor
of activated T-cells; PD: Parkinson’s disease; PKA: Protein kinase A; RILPL: Rab
interacting lysosomal protein like; Roc: Ras of complex proteins; Shh: Sonic
Hedgehog; TB: Tuberculosis; TBK1: TANK-binding kinase 1; TGN: Trans-Golgi
network; TLR: Toll-like receptor; GEF: Guanine nucleotide exchange factor
Acknowledgements
Not applicable
Funding information
KH is supported in part by the Medical Research Council [MR/M00676X/1].
The funder had no role in the decision to publish, or preparation of the
manuscript.
Authors’ contributions
DCB co-wrote the first draft of the manuscript, devised one of the figures
and co-edited the final manuscript; GH led writing of the first draft of the
manuscript; SA contributed to writing the sections on LRRK2 in Parkinson’s
disease and autophagy, and produced two of the figures; KH devised the re-
view structure, produced one of the figures and co-edited the final manu-
script. All authors read and approved the final manuscript.
Availability of data and materials
Not applicable
Ethics approval and consent to participate
Not applicable
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests
Received: 3 June 2019 Accepted: 7 November 2019
References
1. Gan-Or Z, Dion PA, Rouleau GA. Genetic perspective on the role of the
autophagy-lysosome pathway in Parkinson disease. Autophagy. 2015;11(9):
1443–57.
2. Elbaz A, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE,
et al. Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol.
2002;55(1):25–31.
3. Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin
Neurosci. 2002;14(2):223-236; discussion 2.
4. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al.
Mutations in LRRK2 cause autosomal-dominant parkinsonism with
pleomorphic pathology. Neuron. 2004;44(4):601–7.
5. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, et al.
Cloning of the gene containing mutations that cause PARK8-linked
Parkinson's disease. Neuron. 2004;44(4):595–600.
6. Cookson MR. LRRK2 Pathways Leading to Neurodegeneration. Curr Neurol
Neurosci Rep. 2015;15(7):42.
7. International Parkinson Disease Genomics C, Nalls MA, Plagnol V, Hernandez
DG, Sharma M, Sheerin UM, et al. Imputation of sequence variants for
identification of genetic risks for Parkinson's disease: a meta-analysis of
genome-wide association studies. Lancet. 2011;377(9766):641-649.
8. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, et al.
Genome-wide association defines more than 30 distinct susceptibility loci
for Crohn's disease. Nat Genet. 2008;40(8):955–62.
9. Hui KY, Fernandez-Hernandez H, Hu J, Schaffner A, Pankratz N, Hsu NY, et al.
Functional variants in the LRRK2 gene confer shared effects on risk for
Crohn's disease and Parkinson's disease. Sci Transl Med. 2018;10(423).
Berwick et al. Molecular Neurodegeneration           (2019) 14:49 Page 17 of 22
10. Kumar V, Mack DR, Marcil V, Israel D, Krupoves A, Costea I, et al.
Genome-wide association study signal at the 12q12 locus for Crohn's
disease may represent associations with the MUC19 gene. Inflamm
Bowel Dis. 2013;19(6):1254–9.
11. Witoelar A, Jansen IE, Wang Y, Desikan RS, Gibbs JR, Blauwendraat C, et al.
Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune
Diseases. JAMA Neurol. 2017;74(7):780–92.
12. Gajendran M, Loganathan P, Catinella AP, Hashash JG. A comprehensive
review and update on Crohn's disease. Dis Mon. 2018;64(2):20–57.
13. Zhang FR, Huang W, Chen SM, Sun LD, Liu H, Li Y, et al. Genomewide
association study of leprosy. The New Engl J Med. 2009;361(27):2609–18.
14. Marcinek P, Jha AN, Shinde V, Sundaramoorthy A, Rajkumar R, Suryadevara
NC, et al. LRRK2 and RIPK2 variants in the NOD 2-mediated signaling
pathway are associated with susceptibility to Mycobacterium leprae in
Indian populations. PloS One. 2013;8(8):e73103.
15. Wang D, Xu L, Lv L, Su LY, Fan Y, Zhang DF, et al. Association of the LRRK2
genetic polymorphisms with leprosy in Han Chinese from Southwest China.
Genes Immun. 2015;16(2):112–9.
16. Wong SH, Hill AV, Vannberg FO, India-Africa-United Kingdom Leprosy
Genetics C. Genomewide association study of leprosy. The New Engl J Med.
2010;362(15):1446-1447; author reply 7-8.
17. Schurr E, Gros P. A common genetic fingerprint in leprosy and Crohn's
disease? The New Engl J Med. 2009;361(27):2666–8.
18. Wang Z, Arat S, Magid-Slav M, Brown JR. Meta-analysis of human gene
expression in response to Mycobacterium tuberculosis infection reveals
potential therapeutic targets. BMC Syst Biol. 2018;12(1):3.
19. Abel L, Sanchez FO, Oberti J, Thuc NV, Hoa LV, Lap VD, et al. Susceptibility
to leprosy is linked to the human NRAMP1 gene. J Infect Dis. 1998;177(1):
133–45.
20. Shaw MA, Collins A, Peacock CS, Miller EN, Black GF, Sibthorpe D, et al.
Evidence that genetic susceptibility to Mycobacterium tuberculosis in a
Brazilian population is under oligogenic control: linkage study of the
candidate genes NRAMP1 and TNFA. Tuber Lung Dis. 1997;78(1):35–45.
21. Hartlova A, Herbst S, Peltier J, Rodgers A, Bilkei-Gorzo O, Fearns A, et al.
LRRK2 is a negative regulator of Mycobacterium tuberculosis phagosome
maturation in macrophages. The EMBO J. 2018;37(12).
22. Rolli-Derkinderen M, Leclair-Visonneau L, Bourreille A, Coron E, Neunlist M,
Derkinderen P. Is Parkinson's disease a chronic low-grade inflammatory
bowel disease? J Neurol. 2019.
23. Ma Y, Zheng C, Shi L. The kinase LRRK2 is differently expressed in chronic
rhinosinusitis with and without nasal polyps. Clin Transl Allergy. 2018;8:8.
24. Saunders-Pullman R, Barrett MJ, Stanley KM, Luciano MS, Shanker V, Severt L,
et al. LRRK2 G2019S mutations are associated with an increased cancer risk
in Parkinson disease. Mov Dis. 2010;25(15):2536–41.
25. Inzelberg R, Cohen OS, Aharon-Peretz J, Schlesinger I, Gershoni-Baruch R,
Djaldetti R, et al. The LRRK2 G2019S mutation is associated with Parkinson
disease and concomitant non-skin cancers. Neurol. 2012;78(11):781–6.
26. Agalliu I, San Luciano M, Mirelman A, Giladi N, Waro B, Aasly J, et al. Higher
frequency of certain cancers in LRRK2 G2019S mutation carriers with
Parkinson disease: a pooled analysis. JAMA Neurol. 2015;72(1):58–65.
27. Allegra R, Tunesi S, Cilia R, Pezzoli G, Goldwurm S. LRRK2-G2019S mutation
is not associated with an increased cancer risk: a kin-cohort study. Mov Dis.
2014;29(10):1325–6.
28. Ruiz-Martinez J, de la Riva P, Rodriguez-Oroz MC, Mondragon Rezola E,
Bergareche A, Gorostidi A, et al. Prevalence of cancer in Parkinson's
disease related to R1441G and G2019S mutations in LRRK2. Mov Dis.
2014;29(6):750–5.
29. Feng DD, Cai W, Chen X. The associations between Parkinson's disease and
cancer: the plot thickens. Transl Neurodegeneration. 2015;4:20.
30. Marin I. Ancient origin of the Parkinson disease gene LRRK2. J Mol Evol.
2008;67(1):41–50.
31. Deyaert E, Wauters L, Guaitoli G, Konijnenberg A, Leemans M, Terheyden S,
et al. A homologue of the Parkinson's disease-associated protein LRRK2
undergoes a monomer-dimer transition during GTP turnover. Nat Commun.
2017;8(1):1008.
32. Greggio E, Cookson MR. Leucine-rich repeat kinase 2 mutations and
Parkinson's disease: three questions. ASN Neuro. 2009;1(1).
33. Sheng Z, Zhang S, Bustos D, Kleinheinz T, Le Pichon CE, Dominguez SL,
et al. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity
and contributes to the cellular effects of PD mutations. Sci Transl Med.
2012;4(164):164ra1.
34. Steger M, Tonelli F, Ito G, Davies P, Trost M, Vetter M, et al.
Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates
a subset of Rab GTPases. eLife. 2016;5.
35. Steger M, Diez F, Dhekne HS, Lis P, Nirujogi RS, Karayel O, et al. Systematic
proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation
establishes a connection to ciliogenesis. eLife. 2017;6.
36. Madero-Perez J, Fdez E, Fernandez B, Lara Ordonez AJ, Blanca Ramirez M,
Gomez-Suaga P, et al. Parkinson disease-associated mutations in LRRK2
cause centrosomal defects via Rab8a phosphorylation. Mol
Neurodegeneration. 2018;13(1):3.
37. Pfeffer SR. LRRK2 and Rab GTPases. Biochem Soc Trans. 2018;46(6):1707–12.
38. West AB. Achieving neuroprotection with LRRK2 kinase inhibitors in
Parkinson disease. Exp Neurol. 2017;298(Pt B):236–45.
39. Berwick DC, Harvey K. LRRK2 signaling pathways: the key to unlocking
neurodegeneration? Trends Cell Biol. 2011;21(5):257–65.
40. Lewis PA, Manzoni C. LRRK2 and human disease: a complicated question or
a question of complexes? Sci Signal. 2012;5(207):pe2.
41. MacLeod DA, Rhinn H, Kuwahara T, Zolin A, Di Paolo G, McCabe BD, et al.
RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and
Parkinson's disease risk. Neuron. 2013;77(3):425–39.
42. Beilina A, Rudenko IN, Kaganovich A, Civiero L, Chau H, Kalia SK, et al.
Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a
common pathway for sporadic and familial Parkinson disease. Proc Natl
Acad Sci U S A. 2014;111(7):2626–31.
43. Liu Z, Bryant N, Kumaran R, Beilina A, Abeliovich A, Cookson MR, et al.
LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-
bound Rab7L1 to promote recruitment to the trans-Golgi network. Hum
Mol Genet. 2018;27(2):385–95.
44. Purlyte E, Dhekne HS, Sarhan AR, Gomez R, Lis P, Wightman M, et al. Rab29
activation of the Parkinson's disease-associated LRRK2 kinase. The EMBO J.
2018;37(1):1–18.
45. Nixon-Abell J, Berwick DC, Harvey K. L'RRK de Triomphe: a solution for
LRRK2 GTPase activity? Biochem Soc Trans. 2016;44(6):1625–34.
46. Nixon-Abell J, Berwick DC, Granno S, Spain VA, Blackstone C, Harvey K.
Protective LRRK2 R1398H Variant Enhances GTPase and Wnt Signaling
Activity. Front Mol Neurosci. 2016;9:18.
47. Liao J, Wu CX, Burlak C, Zhang S, Sahm H, Wang M, et al. Parkinson disease-
associated mutation R1441H in LRRK2 prolongs the "active state" of its
GTPase domain. Proc Natl Acad Sci U S A. 2014;111(11):4055–60.
48. Mills RD, Liang LY, Lio DS, Mok YF, Mulhern TD, Cao G, et al. The Roc-COR
tandem domain of leucine-rich repeat kinase 2 forms dimers and exhibits
conventional Ras-like GTPase properties. J Neurochem. 2018;147(3):409–28.
49. Xiong Y, Yuan C, Chen R, Dawson TM, Dawson VL. ArfGAP1 is a GTPase
activating protein for LRRK2: reciprocal regulation of ArfGAP1 by LRRK2. The
J Neurosci. 2012;32(11):3877–86.
50. Dusonchet J, Li H, Guillily M, Liu M, Stafa K, Derada Troletti C, et al. A
Parkinson's disease gene regulatory network identifies the signaling protein
RGS2 as a modulator of LRRK2 activity and neuronal toxicity. Hum Mol
Genet. 2014;23(18):4887–905.
51. Haebig K, Gloeckner CJ, Miralles MG, Gillardon F, Schulte C, Riess O, et al.
ARHGEF7 (Beta-PIX) acts as guanine nucleotide exchange factor for leucine-
rich repeat kinase 2. PloS One. 2010;5(10):e13762.
52. Gotthardt K, Weyand M, Kortholt A, Van Haastert PJ, Wittinghofer A. Structure
of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of
the human LRRK2 Parkinson kinase. The EMBO J. 2008;27(16):2239–49.
53. Guaitoli G, Raimondi F, Gilsbach BK, Gomez-Llorente Y, Deyaert E, Renzi F,
et al. Structural model of the dimeric Parkinson's protein LRRK2 reveals a
compact architecture involving distant interdomain contacts. Proc Natl
Acad Sci U S A. 2016;113(30):E4357–66.
54. Wauters L, Versees W, Kortholt A. Roco Proteins: GTPases with a Baroque
Structure and Mechanism. Int J Mol Sci. 2019;20(1).
55. Jorgensen ND, Peng Y, Ho CC, Rideout HJ, Petrey D, Liu P, et al. The WD40
domain is required for LRRK2 neurotoxicity. PloS One. 2009;4(12):e8463.
56. Berger Z, Smith KA, Lavoie MJ. Membrane localization of LRRK2 is associated
with increased formation of the highly active LRRK2 dimer and changes in
its phosphorylation. Biochem. 2010;49(26):5511–23.
57. Sen S, Webber PJ, West AB. Dependence of leucine-rich repeat kinase
2 (LRRK2) kinase activity on dimerization. The J Bio Chem. 2009;
284(52):36346–56.
58. Civiero L, Russo I, Bubacco L, Greggio E. Molecular Insights and Functional
Implication of LRRK2 Dimerization. Adv Neurobiol. 2017;14:107–21.
Berwick et al. Molecular Neurodegeneration           (2019) 14:49 Page 18 of 22
59. James NG, Digman MA, Gratton E, Barylko B, Ding X, Albanesi JP, et al.
Number and brightness analysis of LRRK2 oligomerization in live cells.
Biophys J. 2012;102(11):L41–3.
60. Klein CL, Rovelli G, Springer W, Schall C, Gasser T, Kahle PJ. Homo- and
heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2
ROCO fragment. J Neurochem. 2009;111(3):703–15.
61. Law BM, Spain VA, Leinster VH, Chia R, Beilina A, Cho HJ, et al. A direct
interaction between leucine-rich repeat kinase 2 and specific beta-
tubulin isoforms regulates tubulin acetylation. The J Biol Chem. 2014;
289(2):895–908.
62. Johansen KK, Jorgensen JV, White LR, Farrer MJ, Aasly JO. Parkinson-related
genetics in patients treated with deep brain stimulation. Acta Neurologica
Scandinavica. 2011;123(3):201–6.
63. Zhang P, Fan Y, Ru H, Wang L, Magupalli VG, Taylor SS, et al. Crystal
structure of the WD40 domain dimer of LRRK2. Proc Natl Acad Sci U S A.
2019;116(5):1579–84.
64. Chia R, Haddock S, Beilina A, Rudenko IN, Mamais A, Kaganovich A,
et al. Phosphorylation of LRRK2 by casein kinase 1alpha regulates trans-
Golgi clustering via differential interaction with ARHGEF7. Nat Commun.
2014;5:5827.
65. Dzamko N, Inesta-Vaquera F, Zhang J, Xie C, Cai H, Arthur S, et al. The IkappaB
kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935
and Ser910 during Toll-like receptor signaling. PloS One. 2012;7(6):e39132.
66. Li X, Wang QJ, Pan N, Lee S, Zhao Y, Chait BT, et al. Phosphorylation-
dependent 14-3-3 binding to LRRK2 is impaired by common mutations of
familial Parkinson's disease. PloS One. 2011;6(3):e17153.
67. Muda K, Bertinetti D, Gesellchen F, Hermann JS, von Zweydorf F, Geerlof A,
et al. Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA
phosphorylation of LRRK2 and disrupts its interaction with 14-3-3. Proc Natl
Acad Sci U S A. 2014;111(1):E34-E43.
68. Lobbestael E, Zhao J, Rudenko IN, Beylina A, Gao F, Wetter J, et al.
Identification of protein phosphatase 1 as a regulator of the LRRK2
phosphorylation cycle. The Biochem J. 2013;456(1):119–28.
69. Mamais A, Chia R, Beilina A, Hauser DN, Hall C, Lewis PA, et al. Arsenite
stress down-regulates phosphorylation and 14-3-3 binding of leucine-rich
repeat kinase 2 (LRRK2), promoting self-association and cellular
redistribution. The J Biol Chem. 2014;289(31):21386–400.
70. Hanke ML, Kielian T. Toll-like receptors in health and disease in the brain:
mechanisms and therapeutic potential. Clin Sci. 2011;121(9):367–87.
71. Russo I, Di Benedetto G, Kaganovich A, Ding J, Mercatelli D, Morari M, et al.
Leucine-rich repeat kinase 2 controls protein kinase A activation state
through phosphodiesterase 4. J Neuroinflammation. 2018;15(1):297.
72. Parisiadou L, Yu J, Sgobio C, Xie C, Liu G, Sun L, et al. LRRK2 regulates
synaptogenesis and dopamine receptor activation through modulation of
PKA activity. Nat Neurosci. 2014;17(3):367–76.
73. Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, Tyers M. BioGRID: a
general repository for interaction datasets. Nucleic Acids Res. 2006;
34(Database issue):D535–9.
74. Jia H, Liang Z, Zhang X, Wang J, Xu W, Qian H. 14-3-3 proteins: an
important regulator of autophagy in diseases. Am J Transl Res. 2017;
9(11):4738–46.
75. Nichols RJ, Dzamko N, Morrice NA, Campbell DG, Deak M, Ordureau A, et al.
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-
associated mutations and regulates cytoplasmic localization. The Biochem J.
2010;430(3):393–404.
76. Dzamko N, Deak M, Hentati F, Reith AD, Prescott AR, Alessi DR, et al.
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser (910)/
Ser (935), disruption of 14-3-3 binding and altered cytoplasmic localization.
The Biochem J. 2010;430(3):405–13.
77. Lavalley NJ, Slone SR, Ding H, West AB, Yacoubian TA. 14-3-3 Proteins
regulate mutant LRRK2 kinase activity and neurite shortening. Hum Mol
Genet. 2016;25(1):109–22.
78. Hsu CH, Chan D, Wolozin B. LRRK2 and the stress response: interaction with
MKKs and JNK-interacting proteins. Neurodegener Dis. 2010;7(1-3):68–75.
79. Hsu CH, Chan D, Greggio E, Saha S, Guillily MD, Ferree A, et al. MKK6 binds
and regulates expression of Parkinson's disease-related protein LRRK2. J
Neurochem. 2010;112(6):1593–604.
80. Gloeckner CJ, Schumacher A, Boldt K, Ueffing M. The Parkinson
disease-associated protein kinase LRRK2 exhibits MAPKKK activity and
phosphorylates MKK3/6 and MKK4/7, in vitro. J Neurochem. 2009;
109(4):959–68.
81. Ohta E, Kawakami F, Kubo M, Obata F. LRRK2 directly phosphorylates Akt1 as a
possible physiological substrate: impairment of the kinase activity by
Parkinson's disease-associated mutations. FEBS Letters. 2011;585(14):2165–70.
82. Imai Y, Kobayashi Y, Inoshita T, Meng H, Arano T, Uemura K, et al. The
Parkinson's Disease-Associated Protein Kinase LRRK2 Modulates Notch
Signaling through the Endosomal Pathway. PLoS Genet. 2015;11(9):e1005503.
83. Ho CC, Rideout HJ, Ribe E, Troy CM, Dauer WT. The Parkinson disease
protein leucine-rich repeat kinase 2 transduces death signals via Fas-
associated protein with death domain and caspase-8 in a cellular model of
neurodegeneration. The J Neurosci. 2009;29(4):1011–6.
84. Gardet A, Benita Y, Li C, Sands BE, Ballester I, Stevens C, et al. LRRK2 is
involved in the IFN-gamma response and host response to pathogens. J
Immunol. 2010;185(9):5577–85.
85. Kim B, Yang MS, Choi D, Kim JH, Kim HS, Seol W, et al. Impaired
inflammatory responses in murine Lrrk2-knockdown brain microglia. PloS
One. 2012;7(4):e34693.
86. Russo I, Berti G, Plotegher N, Bernardo G, Filograna R, Bubacco L, et al.
Leucine-rich repeat kinase 2 positively regulates inflammation and down-
regulates NF-kappaB p50 signaling in cultured microglia cells. J
Neuroinflammation. 2015;12:230.
87. Lopez de Maturana R, Aguila JC, Sousa A, Vazquez N, Del Rio P, Aiastui A,
et al. Leucine-rich repeat kinase 2 modulates cyclooxygenase 2 and the
inflammatory response in idiopathic and genetic Parkinson's disease.
Neurobiol Aging. 2014;35(5):1116–24.
88. Lopez de Maturana R, Lang V, Zubiarrain A, Sousa A, Vazquez N, Gorostidi A,
et al. Mutations in LRRK2 impair NF-kappaB pathway in iPSC-derived
neurons. J Neuroinflammation. 2016;13(1):295.
89. Korecka JA, Talbot S, Osborn TM, de Leeuw SM, Levy SA, Ferrari EJ, et al.
Neurite Collapse and Altered ER Ca (2+) Control in Human Parkinson
Disease Patient iPSC-Derived Neurons with LRRK2 G2019S Mutation. Stem
Cell Rep. 2019;12(1):29–41.
90. Verma M, Callio J, Otero PA, Sekler I, Wills ZP, Chu CT. Mitochondrial
Calcium Dysregulation Contributes to Dendrite Degeneration Mediated by
PD/LBD-Associated LRRK2 Mutants. The J Neurosci. 2017;37(46):11151–65.
91. Schwab AJ, Ebert AD. Neurite Aggregation and Calcium Dysfunction in
iPSC-Derived Sensory Neurons with Parkinson's Disease-Related LRRK2
G2019S Mutation. Stem Cell Rep. 2015;5(6):1039–52.
92. Cherra SJ 3rd, Steer E, Gusdon AM, Kiselyov K, Chu CT. Mutant LRRK2 elicits
calcium imbalance and depletion of dendritic mitochondria in neurons. The
Am J Pathol. 2013;182(2):474–84.
93. Bedford C, Sears C, Perez-Carrion M, Piccoli G, Condliffe SB. LRRK2 Regulates
Voltage-Gated Calcium Channel Function. Front Mol Neurosci. 2016;9:35.
94. Yan J, Almilaji A, Schmid E, Elvira B, Shimshek DR, van der Putten H, et al.
Leucine-rich repeat kinase 2-sensitive Na+/Ca2+ exchanger activity in
dendritic cells. FASEB J. 2015;29(5):1701–10.
95. Piccoli G, Condliffe SB, Bauer M, Giesert F, Boldt K, De Astis S, et al. LRRK2
controls synaptic vesicle storage and mobilization within the recycling pool.
The J Neurosci. 2011;31(6):2225–37.
96. Matikainen-Ankney BA, Kezunovic N, Menard C, Flanigan ME, Zhong Y,
Russo SJ, et al. Parkinson's Disease-Linked LRRK2-G2019S Mutation Alters
Synaptic Plasticity and Promotes Resilience to Chronic Social Stress in
Young Adulthood. The J Neurosci. 2018;38(45):9700–11.
97. Gomez-Suaga P, Luzon-Toro B, Churamani D, Zhang L, Bloor-Young D, Patel S,
et al. Leucine-rich repeat kinase 2 regulates autophagy through a calcium-
dependent pathway involving NAADP. Hum Mol Genet. 2012;21(3):511–25.
98. Hockey LN, Kilpatrick BS, Eden ER, Lin-Moshier Y, Brailoiu GC, Brailoiu E, et al.
Dysregulation of lysosomal morphology by pathogenic LRRK2 is corrected
by TPC2 inhibition. J Cell Sci. 2015;128(2):232–8.
99. Liu Z, Lee J, Krummey S, Lu W, Cai H, Lenardo MJ. The kinase LRRK2 is a
regulator of the transcription factor NFAT that modulates the severity of
inflammatory bowel disease. Nat Immunol. 2011;12(11):1063–70.
100. Moore DL, Goldberg JL. Multiple transcription factor families regulate axon
growth and regeneration. Dev Neurobiol. 2011;71(12):1186–211.
101. Harvey K, Outeiro TF. The role of LRRK2 in cell signalling. Biochem Soc
Trans. 2019;47(1):197–207.
102. Berwick DC, Harvey K. LRRK2 functions as a Wnt signaling scaffold, bridging
cytosolic proteins and membrane-localized LRP6. Hum Mol Genet. 2012;
21(22):4966–79.
103. Sancho RM, Law BM, Harvey K. Mutations in the LRRK2 Roc-COR tandem
domain link Parkinson's disease to Wnt signalling pathways. Hum Mol
Genet. 2009;18(20):3955–68.
Berwick et al. Molecular Neurodegeneration           (2019) 14:49 Page 19 of 22
104. Salasova A, Yokota C, Potesil D, Zdrahal Z, Bryja V, Arenas E. A proteomic
analysis of LRRK2 binding partners reveals interactions with multiple
signaling components of the WNT/PCP pathway. Mol Neurodegeneration.
2017;12(1):54.
105. Berwick DC, Javaheri B, Wetzel A, Hopkinson M, Nixon-Abell J, Granno S,
et al. Pathogenic LRRK2 variants are gain-of-function mutations that
enhance LRRK2-mediated repression of beta-catenin signaling. M
Neurodegeneration. 2017;12(1):9.
106. Lin CH, Tsai PI, Wu RM, Chien CT. LRRK2 G2019S mutation induces dendrite
degeneration through mislocalization and phosphorylation of tau by
recruiting autoactivated GSK3ss. The J Neurosci. 2010;30(39):13138–49.
107. Kawakami F, Shimada N, Ohta E, Kagiya G, Kawashima R, Maekawa T, et al.
Leucine-rich repeat kinase 2 regulates tau phosphorylation through direct
activation of glycogen synthase kinase-3beta. The FEBS J. 2014;281(1):3–13.
108. Berwick DC, Harvey K. The importance of Wnt signalling for
neurodegeneration in Parkinson's disease. Biochem Soc Trans. 2012;
40(5):1123–8.
109. Kawakami F, Yabata T, Ohta E, Maekawa T, Shimada N, Suzuki M, et al.
LRRK2 phosphorylates tubulin-associated tau but not the free molecule:
LRRK2-mediated regulation of the tau-tubulin association and neurite
outgrowth. PloS One. 2012;7(1):e30834.
110. Hamm M, Bailey R, Shaw G, Yen SH, Lewis J, Giasson BI. Physiologically
relevant factors influence tau phosphorylation by leucine-rich repeat kinase
2. J Neurosci Res. 2015;93(10):1567–80.
111. Guerreiro PS, Gerhardt E. Lopes da Fonseca T, Bahr M, Outeiro TF,
Eckermann K. LRRK2 Promotes Tau Accumulation, Aggregation and Release.
Mol Neurobiol. 2016;53(5):3124–35.
112. Tapia-Rojas C, Inestrosa NC. Loss of canonical Wnt signaling is involved
in the pathogenesis of Alzheimer's disease. Neural Regen Res. 2018;
13(10):1705–10.
113. Houlden H, Singleton AB. The genetics and neuropathology of Parkinson's
disease. Acta Neuropathol. 2012;124(3):325–38.
114. Khan NL, Jain S, Lynch JM, Pavese N, Abou-Sleiman P, Holton JL, et al.
Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial
Parkinson's disease: clinical, pathological, olfactory and functional imaging
and genetic data. Brain. 2005;128(Pt 12):2786–96.
115. Chan D, Citro A, Cordy JM, Shen GC, Wolozin B. Rac1 protein rescues
neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2).
The J Biol Chem. 2011;286(18):16140–9.
116. Schapansky J, Khasnavis S, DeAndrade MP, Nardozzi JD, Falkson SR, Boyd JD,
et al. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and
accumulation of endogenous insoluble alpha-synuclein in neurons.
Neurobiol Dis. 2018;111:26–35.
117. Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, et al. Mutant
LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of
Parkinson's disease. Nat Neurosci. 2009;12(7):826–8.
118. Melrose HL, Dachsel JC, Behrouz B, Lincoln SJ, Yue M, Hinkle KM, et al.
Impaired dopaminergic neurotransmission and microtubule-associated
protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis.
2010;40(3):503–17.
119. Biskup S, Moore DJ, Celsi F, Higashi S, West AB, Andrabi SA, et al.
Localization of LRRK2 to membranous and vesicular structures in
mammalian brain. Ann Neurol. 2006;60(5):557–69.
120. Melrose HL, Kent CB, Taylor JP, Dachsel JC, Hinkle KM, Lincoln SJ, et al. A
comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in
mouse brain and Lewy body disease. Neurosci. 2007;147(4):1047–58.
121. Davies P, Hinkle KM, Sukar NN, Sepulveda B, Mesias R, Serrano G,
et al. Comprehensive characterization and optimization of anti-LRRK2
(leucine-rich repeat kinase 2) monoclonal antibodies. The Biochem J.
2013;453(1):101–13.
122. Alegre-Abarrategui J, Christian H, Lufino MM, Mutihac R, Venda LL, Ansorge
O, et al. LRRK2 regulates autophagic activity and localizes to specific
membrane microdomains in a novel human genomic reporter cellular
model. Hum Mol Genet. 2009;18(21):4022–34.
123. Schreij AM, Chaineau M, Ruan W, Lin S, Barker PA, Fon EA, et al. LRRK2
localizes to endosomes and interacts with clathrin-light chains to limit Rac1
activation. EMBO Rep. 2015;16(1):79–86.
124. Eguchi T, Kuwahara T, Sakurai M, Komori T, Fujimoto T, Ito G, et al. LRRK2
and its substrate Rab GTPases are sequentially targeted onto stressed
lysosomes and maintain their homeostasis. Proc Natl Acad Sci U S A. 2018;
115(39):E9115–E24.
125. Dikic I, Elazar Z. Mechanism and medical implications of mammalian
autophagy. Nat Rev Mol Cell Biol. 2018;19(6):349–64.
126. Tong Y, Yamaguchi H, Giaime E, Boyle S, Kopan R, Kelleher RJ 3rd, et al. Loss
of leucine-rich repeat kinase 2 causes impairment of protein degradation
pathways, accumulation of alpha-synuclein, and apoptotic cell death in
aged mice. Proc Natl Acad Sci U S A. 2010;107(21):9879–84.
127. Tong Y, Giaime E, Yamaguchi H, Ichimura T, Liu Y, Si H, et al. Loss of
leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of
the autophagy pathway. Mol Neurodegeneration. 2012;7:2.
128. Kuwahara T, Inoue K, D'Agati VD, Fujimoto T, Eguchi T, Saha S, et al. LRRK2
and RAB7L1 coordinately regulate axonal morphology and lysosome
integrity in diverse cellular contexts. Sci Rep. 2016;6:29945.
129. Pellegrini L, Hauser DN, Li Y, Mamais A, Beilina A, Kumaran R, et al.
Proteomic analysis reveals co-ordinated alterations in protein synthesis and
degradation pathways in LRRK2 knockout mice. Hum Mol Genet. 2018;
27(18):3257–71.
130. Giaime E, Tong Y, Wagner LK, Yuan Y, Huang G, Shen J. Age-Dependent
Dopaminergic Neurodegeneration and Impairment of the Autophagy-
Lysosomal Pathway in LRRK-Deficient Mice. Neuron. 2017;96(4):796-807 e6.
131. Manzoni C. The LRRK2-macroautophagy axis and its relevance to Parkinson's
disease. Biochem Soc Trans. 2017;45(1):155–62.
132. Manzoni C, Mamais A, Dihanich S, Abeti R, Soutar MP, Plun-Favreau H, et al.
Inhibition of LRRK2 kinase activity stimulates macroautophagy. Biochim
Biophys Acta. 2013;1833(12):2900–10.
133. Saez-Atienzar S, Bonet-Ponce L, Blesa JR, Romero FJ, Murphy MP, Jordan J,
et al. The LRRK2 inhibitor GSK2578215A induces protective autophagy in
SH-SY5Y cells: involvement of Drp-1-mediated mitochondrial fission and
mitochondrial-derived ROS signaling. Cell Death Dis. 2014;5:e1368.
134. Manzoni C, Mamais A, Roosen DA, Dihanich S, Soutar MP, Plun-Favreau H,
et al. mTOR independent regulation of macroautophagy by Leucine Rich
Repeat Kinase 2 via Beclin-1. Sci Rep. 2016;6:35106.
135. Schapansky J, Nardozzi JD, Felizia F, LaVoie MJ. Membrane recruitment of
endogenous LRRK2 precedes its potent regulation of autophagy. Hum Mol
Genet. 2014;23(16):4201–14.
136. Cherra SJ 3rd, Kulich SM, Uechi G, Balasubramani M, Mountzouris J, Day BW,
et al. Regulation of the autophagy protein LC3 by phosphorylation. The J
Cell Biol. 2010;190(4):533–9.
137. Plowey ED, Cherra SJ 3rd, Liu YJ, Chu CT. Role of autophagy in G2019S-
LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J
Neurochem. 2008;105(3):1048–56.
138. Manzoni C, Mamais A, Dihanich S, McGoldrick P, Devine MJ, Zerle J, et al.
Pathogenic Parkinson's disease mutations across the functional domains of
LRRK2 alter the autophagic/lysosomal response to starvation. Biochem
Biophys Res Commun. 2013;441(4):862–6.
139. Kaushik S, Cuervo AM. The coming of age of chaperone-mediated
autophagy. Nat Rev Mol Cell Biol. 2018;19(6):365–81.
140. Orenstein SJ, Kuo SH, Tasset I, Arias E, Koga H, Fernandez-Carasa I, et al.
Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci.
2013;16(4):394–406.
141. Shin N, Jeong H, Kwon J, Heo HY, Kwon JJ, Yun HJ, et al. LRRK2 regulates
synaptic vesicle endocytosis. Exp Cell Res. 2008;314(10):2055–65.
142. Woodman PG. Biogenesis of the sorting endosome: the role of Rab5. Traffic.
2000;1(9):695–701.
143. Yun HJ, Kim H, Ga I, Oh H, Ho DH, Kim J, et al. An early endosome
regulator, Rab5b, is an LRRK2 kinase substrate. J Biochem. 2015;157(6):
485–95.
144. Dodson MW, Zhang T, Jiang C, Chen S, Guo M. Roles of the Drosophila
LRRK2 homolog in Rab7-dependent lysosomal positioning. Hum Mol Genet.
2012;21(6):1350–63.
145. Gomez-Suaga P, Rivero-Rios P, Fdez E, Blanca Ramirez M, Ferrer I, Aiastui A,
et al. LRRK2 delays degradative receptor trafficking by impeding late
endosomal budding through decreasing Rab7 activity. Hum Mol Genet.
2014;23(25):6779–96.
146. Rivero-Rios P, Romo-Lozano M, Madero-Perez J, Thomas AP, Biosa A,
Greggio E, et al. The G2019S variant of leucine-rich repeat kinase 2 (LRRK2)
alters endolysosomal trafficking by impairing the function of the GTPase
RAB8A. The J Biol Chem. 2019;294(13):4738–58.
147. Cirnaru MD, Marte A, Belluzzi E, Russo I, Gabrielli M, Longo F, et al. LRRK2
kinase activity regulates synaptic vesicle trafficking and neurotransmitter
release through modulation of LRRK2 macro-molecular complex. Front Mol
Neurosci. 2014;7:49.
Berwick et al. Molecular Neurodegeneration           (2019) 14:49 Page 20 of 22
148. Matta S, Van Kolen K, da Cunha R, van den Bogaart G, Mandemakers W,
Miskiewicz K, et al. LRRK2 controls an EndoA phosphorylation cycle in
synaptic endocytosis. Neuron. 2012;75(6):1008–21.
149. Arranz AM, Delbroek L, Van Kolen K, Guimaraes MR, Mandemakers W,
Daneels G, et al. LRRK2 functions in synaptic vesicle endocytosis through a
kinase-dependent mechanism. J Cell Sci. 2015;128(3):541–52.
150. Pan PY, Li X, Wang J, Powell J, Wang Q, Zhang Y, et al. Parkinson's
Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic
Vesicle Trafficking in Ventral Midbrain Neurons. The J Neurosci. 2017;
37(47):11366–76.
151. Soukup SF, Kuenen S, Vanhauwaert R, Manetsberger J, Hernandez-Diaz S,
Swerts J, et al. A LRRK2-Dependent EndophilinA Phosphoswitch Is Critical
for Macroautophagy at Presynaptic Terminals. Neuron. 2016;92(4):829–44.
152. Li X, Patel JC, Wang J, Avshalumov MV, Nicholson C, Buxbaum JD, et al.
Enhanced striatal dopamine transmission and motor performance with
LRRK2 overexpression in mice is eliminated by familial Parkinson's disease
mutation G2019S. The J Neurosci. 2010;30(5):1788–97.
153. Beccano-Kelly DA, Volta M, Munsie LN, Paschall SA, Tatarnikov I, Co K, et al.
LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal
dopamine tone, postsynaptic signal transduction, motor activity and
memory. Hum Mol Genet. 2015;24(5):1336–49.
154. Sweet ES, Saunier-Rebori B, Yue Z, Blitzer RD. The Parkinson's Disease-
Associated Mutation LRRK2-G2019S Impairs Synaptic Plasticity in Mouse
Hippocampus. The J Neurosci. 2015;35(32):11190–5.
155. Krebs CE, Karkheiran S, Powell JC, Cao M, Makarov V, Darvish H, et al. The
Sac1 domain of SYNJ1 identified mutated in a family with early-onset
progressive Parkinsonism with generalized seizures. Human Mutat. 2013;
34(9):1200–7.
156. Quadri M, Fang M, Picillo M, Olgiati S, Breedveld GJ, Graafland J, et al.
Mutation in the SYNJ1 gene associated with autosomal recessive, early-
onset Parkinsonism. Human Mutat. 2013;34(9):1208–15.
157. Edvardson S, Cinnamon Y, Ta-Shma A, Shaag A, Yim YI, Zenvirt S, et al.
A deleterious mutation in DNAJC6 encoding the neuronal-specific
clathrin-uncoating co-chaperone auxilin, is associated with juvenile
parkinsonism. PloS One. 2012;7(5):e36458.
158. Ungewickell E, Ungewickell H, Holstein SE, Lindner R, Prasad K, Barouch W,
et al. Role of auxilin in uncoating clathrin-coated vesicles. Nat. 1995;
378(6557):632–5.
159. Nguyen M, Krainc D. LRRK2 phosphorylation of auxilin mediates synaptic
defects in dopaminergic neurons from patients with Parkinson's disease.
Proc Natl Acad Sci U S A. 2018;115(21):5576–81.
160. Islam MS, Nolte H, Jacob W, Ziegler AB, Putz S, Grosjean Y, et al. Human
R1441C LRRK2 regulates the synaptic vesicle proteome and
phosphoproteome in a Drosophila model of Parkinson's disease. Hum Mol
Genet. 2016;25(24):5365–82.
161. Abeliovich A, Gitler AD. Defects in trafficking bridge Parkinson's disease
pathology and genetics. Nat. 2016;539(7628):207–16.
162. Bandres-Ciga S, Saez-Atienzar S, Bonet-Ponce L, Billingsley K, Vitale D,
Blauwendraat C, et al. The endocytic membrane trafficking pathway plays a
major role in the risk of Parkinson's disease. Mov Disord. 2019;34(4):460–8.
163. Seaman MN. Recycle your receptors with retromer. Trends Cell Biol. 2005;
15(2):68–75.
164. Zimprich A, Benet-Pages A, Struhal W, Graf E, Eck SH, Offman MN, et al. A
mutation in VPS35, encoding a subunit of the retromer complex, causes
late-onset Parkinson disease. Am J Hum Genet. 2011;89(1):168–75.
165. Vilarino-Guell C, Wider C, Ross OA, Dachsel JC, Kachergus JM, Lincoln SJ, et al.
VPS35 mutations in Parkinson disease. Am J Hum Genet. 2011;89(1):162–7.
166. Kalia SK, Lee S, Smith PD, Liu L, Crocker SJ, Thorarinsdottir TE, et al. BAG5
inhibits parkin and enhances dopaminergic neuron degeneration. Neuron.
2004;44(6):931–45.
167. Dawson TM, Dawson VL. The role of parkin in familial and sporadic
Parkinson's disease. Mov Disord. 2010;25(Suppl 1):S32–9.
168. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD.
Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem.
1990;54(3):823–7.
169. Langston JW, Forno LS, Rebert CS, Irwin I. Selective nigral toxicity after
systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine
(MPTP) in the squirrel monkey. Brain Res. 1984;292(2):390–4.
170. Cicchetti F, Drouin-Ouellet J, Gross RE. Environmental toxins and Parkinson's
disease: what have we learned from pesticide-induced animal models?
Trends Pharmacol Sci. 2009;30(9):475–83.
171. Sherer TB, Richardson JR, Testa CM, Seo BB, Panov AV, Yagi T, et al. Mechanism
of toxicity of pesticides acting at complex I: relevance to environmental
etiologies of Parkinson's disease. J Neurochem. 2007;100(6):1469–79.
172. van der Merwe C. Jalali Sefid Dashti Z, Christoffels A, Loos B, Bardien S.
Evidence for a common biological pathway linking three Parkinson's
disease-causing genes: parkin, PINK1 and DJ-1. The Eur J Neurosci. 2015;
41(9):1113–25.
173. Trancikova A, Tsika E, Moore DJ. Mitochondrial dysfunction in genetic
animal models of Parkinson's disease. Antioxid Redox Signal. 2012;16(9):
896–919.
174. Ahlskog JE. Parkin and PINK1 parkinsonism may represent nigral
mitochondrial cytopathies distinct from Lewy body Parkinson's disease.
Parkinsonism Relat Disord. 2009;15(10):721–7.
175. Ng CH, Mok SZ, Koh C, Ouyang X, Fivaz ML, Tan EK, et al. Parkin protects
against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in
Drosophila. The J Neurosci. 2009;29(36):11257–62.
176. Karuppagounder SS, Xiong Y, Lee Y, Lawless MC, Kim D, Nordquist E, et al.
LRRK2 G2019S transgenic mice display increased susceptibility to 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated neurotoxicity. J Chem
Neuroanat. 2016.
177. Cooper O, Seo H, Andrabi S, Guardia-Laguarta C, Graziotto J, Sundberg M,
et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived
neural cells from patients with familial Parkinson's disease. Sci Transl Med.
2012;4(141):141ra90.
178. Nguyen HN, Byers B, Cord B, Shcheglovitov A, Byrne J, Gujar P, et al. LRRK2
mutant iPSC-derived DA neurons demonstrate increased susceptibility to
oxidative stress. Cell Stem Cell. 2011;8(3):267–80.
179. Angeles DC, Gan BH, Onstead L, Zhao Y, Lim KL, Dachsel J, et al. Mutations
in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating
oxidative stress-induced neuronal death. Hum Mutat. 2011;32(12):1390–7.
180. Angeles DC, Ho P, Chua LL, Wang C, Yap YW, Ng C, et al. Thiol peroxidases
ameliorate LRRK2 mutant-induced mitochondrial and dopaminergic
neuronal degeneration in Drosophila. Hum Mol Genet. 2014;23(12):3157–65.
181. Mortiboys H, Furmston R, Bronstad G, Aasly J, Elliott C, Bandmann O. UDCA
exerts beneficial effect on mitochondrial dysfunction in LRRK2(G2019S)
carriers and in vivo. Neurol. 2015;85(10):846–52.
182. Yue M, Hinkle KM, Davies P, Trushina E, Fiesel FC, Christenson TA, et al.
Progressive dopaminergic alterations and mitochondrial abnormalities in
LRRK2 G2019S knock-in mice. Neurobiol Dis. 2015;78:172–95.
183. Grunewald A, Arns B, Meier B, Brockmann K, Tadic V, Klein C. Does uncoupling
protein 2 expression qualify as marker of disease status in LRRK2-associated
Parkinson's disease? Antioxid Redox Signal. 2014;20(13):1955–60.
184. Smith GA, Jansson J, Rocha EM, Osborn T, Hallett PJ, Isacson O. Fibroblast
Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition. Mol
Neurobiol. 2015.
185. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, et al.
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2
augment kinase activity. Proc Natl Acad Sci U S A. 2005;102(46):16842–7.
186. Hsieh CH, Shaltouki A, Gonzalez AE. Bettencourt da Cruz A, Burbulla LF, St
Lawrence E, et al. Functional Impairment in Miro Degradation and
Mitophagy Is a Shared Feature in Familial and Sporadic Parkinson's Disease.
Cell Stem Cell. 2016;19(6):709–24.
187. Godena VK, Brookes-Hocking N, Moller A, Shaw G, Oswald M, Sancho RM,
et al. Increasing microtubule acetylation rescues axonal transport and
locomotor deficits caused by LRRK2 Roc-COR domain mutations. Nat
Commun. 2014;5:5245.
188. Thomas JM, Li T, Yang W, Xue F, Fishman PS, Smith WW. 68 and FX2149
Attenuate Mutant LRRK2-R1441C-Induced Neural Transport Impairment.
Front Aging Neurosci. 2016;8:337.
189. Schwarz DS, Blower MD. The endoplasmic reticulum: structure, function and
response to cellular signaling. Cell Mol Life Sci. 2016;73(1):79–94.
190. Tsujii S, Ishisaka M, Hara H. Modulation of endoplasmic reticulum stress in
Parkinson's disease. Eur J Pharmacol. 2015;765:154–6.
191. Vitte J, Traver S. Maues De Paula A, Lesage S, Rovelli G, Corti O, et al.
Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum
in dopaminergic neurons and accumulates in the core of Lewy bodies in
Parkinson disease. J Neuropathol Exp Neurol. 2010;69(9):959–72.
192. Yuan Y, Cao P, Smith MA, Kramp K, Huang Y, Hisamoto N, et al.
Dysregulated LRRK2 signaling in response to endoplasmic reticulum
stress leads to dopaminergic neuron degeneration in C. elegans. PloS
One. 2011;6(8):e22354.
Berwick et al. Molecular Neurodegeneration           (2019) 14:49 Page 21 of 22
193. Cho HJ, Yu J, Xie C, Rudrabhatla P, Chen X, Wu J, et al. Leucine-rich repeat
kinase 2 regulates Sec16A at ER exit sites to allow ER-Golgi export. The
EMBO J. 2014;33(20):2314–31.
194. Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, Oota E, et al.
Phosphorylation of 4E-BP by LRRK2 affects the maintenance of
dopaminergic neurons in Drosophila. The EMBO J. 2008;27(18):2432–43.
195. Penney J, Tsurudome K, Liao EH, Kauwe G, Gray L, Yanagiya A, et al. LRRK2
regulates retrograde synaptic compensation at the Drosophila
neuromuscular junction. Nat Commun. 2016;7:12188.
196. Trancikova A, Mamais A, Webber PJ, Stafa K, Tsika E, Glauser L, et al.
Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2
expression or pathogenic mutations. PloS One. 2012;7(10):e47784.
197. Kumar A, Greggio E, Beilina A, Kaganovich A, Chan D, Taymans JM, et al. The
Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation
of 4E-BP compared to autophosphorylation. PloS One. 2010;5(1):e8730.
198. Martin I, Kim JW, Lee BD, Kang HC, Xu JC, Jia H, et al. Ribosomal protein s15
phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease.
Cell. 2014;157(2):472–85.
199. Gehrke S, Imai Y, Sokol N, Lu B. Pathogenic LRRK2 negatively regulates
microRNA-mediated translational repression. Nat. 2010;466(7306):637–41.
200. Pellegrini L, Wetzel A, Granno S, Heaton G, Harvey K. Back to the tubule:
microtubule dynamics in Parkinson's disease. Cell Mol Life Sci. 2017;74(3):409–34.
201. Outeiro TF, Harvey K, Dominguez-Meijide A, Gerhardt E. LRRK2, alpha-synuclein,
and tau: partners in crime or unfortunate bystanders? Biochem Soc Trans. 2019.
202. Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O'Neill E, Meitinger T, et al.
The Parkinson disease causing LRRK2 mutation I2020T is associated with
increased kinase activity. Hum Mol Genet. 2006;15(2):223–32.
203. Perdiz D, Mackeh R, Pous C, Baillet A. The ins and outs of tubulin acetylation:
more than just a post-translational modification? Cell Signal. 2011;23(5):763–71.
204. Pala R, Alomari N, Nauli SM. Primary Cilium-Dependent Signaling
Mechanisms. Int J Mol Sci. 2017;18(11).
205. Dhekne HS, Yanatori I, Gomez RC, Tonelli F, Diez F, Schule B, et al. A
pathway for Parkinson's Disease LRRK2 kinase to block primary cilia and
Sonic hedgehog signaling in the brain. eLife. 2018;7.
206. Werner S, Pimenta-Marques A, Bettencourt-Dias M. Maintaining
centrosomes and cilia. J Cell Sci. 2017;130(22):3789–800.
207. Madero-Perez J, Fernandez B, Lara Ordonez AJ, Fdez E, Lobbestael E, Baekelandt
V, et al. RAB7L1-Mediated Relocalization of LRRK2 to the Golgi Complex Causes
Centrosomal Deficits via RAB8A. Front Mol Neurosci. 2018;11:417.
208. Dehay B, Martinez-Vicente M, Caldwell GA, Caldwell KA, Yue Z, Cookson MR, et al.
Lysosomal impairment in Parkinson's disease. Mov Disord. 2013;28(6):725–32.
209. Ryan BJ, Hoek S, Fon EA, Wade-Martins R. Mitochondrial dysfunction and
mitophagy in Parkinson's: from familial to sporadic disease. Trends Biochem
Sci. 2015;40(4):200–10.
210. Taelman VF, Dobrowolski R, Plouhinec JL, Fuentealba LC, Vorwald PP,
Gumper I, et al. Wnt signaling requires sequestration of glycogen synthase
kinase 3 inside multivesicular endosomes. Cell. 2010;143(7):1136–48.
211. Harvey K, Marchetti B. Regulating Wnt signaling: a strategy to prevent
neurodegeneration and induce regeneration. J Mol Cell Bio. 2014;6(1):1–2.
212. L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Serapide MF, et al.
Wnt/beta-catenin signaling is required to rescue midbrain dopaminergic
progenitors and promote neurorepair in ageing mouse model of
Parkinson's disease. Stem Cells. 2014;32(8):2147–63.
213. Decressac M, Mattsson B, Weikop P, Lundblad M, Jakobsson J, Bjorklund A. TFEB-
mediated autophagy rescues midbrain dopamine neurons from alpha-synuclein
toxicity. Proc Natl Acad Sci U S A. 2013;110(19):E1817–26.
214. Xilouri M, Brekk OR, Landeck N, Pitychoutis PM, Papasilekas T, Papadopoulou-
Daifoti Z, et al. Boosting chaperone-mediated autophagy in vivo mitigates alpha-
synuclein-induced neurodegeneration. Brain. 2013;136(Pt 7):2130–46.
215. Berwick DC, Harvey K. LRRK2: an eminence grise of Wnt-mediated
neurogenesis? Front Cell Neurosci. 2013;7:82.
216. Schaffner A, Li X, Gomez-Llorente Y, Leandrou E, Memou A, Clemente N, et al.
Vitamin B12 modulates Parkinson's disease LRRK2 kinase activity through
allosteric regulation and confers neuroprotection. Cell Res. 2019;29(4):313–29.
217. Blanca Ramirez M, Lara Ordonez AJ, Fdez E, Madero-Perez J, Gonnelli A,
Drouyer M, et al. GTP binding regulates cellular localization of Parkinson's
disease-associated LRRK2. Hum Mol Genet. 2017;26(14):2747–67.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Berwick et al. Molecular Neurodegeneration           (2019) 14:49 Page 22 of 22
